

Analysis Data Reviewer's Guide

sBLA (12-15 Years of Age)

BioNTech SE and PFIZER INC.

Study C4591001

ANALYSIS DATA REVIEWER'S GUIDE

REVISION HISTORY

Version	Summary of Major Change(s) and Impact	Version Date
1.0	First approved version of Analysis Data Reviewer Guide	14-Dec-2021

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

1. Introduction	5
1.1 Purpose.....	5
1.2 Acronyms.....	6
1.3 Study Data Standards and Dictionary Inventory	7
1.4 Source Data Used for Analysis Dataset Creation.....	7
2. Protocol Description.....	7
2.1 Protocol Number and Title	7
2.2 Protocol Design in Relation to ADaM Concepts.....	9
3. Analysis Considerations Related to Multiple Analysis Datasets	11
3.1 Study Populations and Core Variables.....	11
3.2 Treatment Variable.....	16
3.3 Subject Issues that Require Special Analysis Rules	18
3.4 Use of Visit Windowing, Unscheduled Visits, and Record Selection	20
3.5 Imputation/Derivation Methods	20
4. Analysis Data Creation and Processing Issues	20
4.1 Split Datasets.....	20
4.2 Data Dependencies	20
4.3 Intermediate Datasets	20
5. Analysis Dataset Descriptions	20
5.1 Overview	20
5.2 Analysis Datasets	21
5.2.1 ADSL – Subject-Level Analysis Dataset	22
5.2.2 ADCEVD – Diary and CRF Event Analysis Dataset	23
5.2.3 ADAE – Adverse Events Analysis Dataset.....	23
5.2.4 ADCM – Concomitant Medications Analysis Dataset.....	23
5.2.5 ADDS – Disposition Analysis Dataset	24
5.2.6 ADDV – Protocol Deviation Analysis Dataset	24
5.2.7 ADFACEVD – Diary and Non-event Analysis Dataset.....	24
5.2.8 ADMH – Medical History Analysis Dataset	26
5.2.9 ADSYMPT – Covid-19 Signs and Symptoms.....	26
5.2.10 ADC19EF – Covid-19 Efficacy Analysis	29
5.2.11 ADVA – Immunogenicity Analysis Dataset.....	31
6. Data Conformance Summary	32
6.1 Conformance Inputs	32
6.2 Issues Summary (Pinnacle 21 Enterprise Validation Report).....	33
7. Submission of Programs.....	36
7.1 ADaM Programs	36
7.2 Analysis Output Programs.....	36
8. Appendix	39

Appendix I: Annotated Mocks for Key Tables.....39

Appendix II: Analysis plan AE windowing logic51

Appendix III: Handling of Incomplete Dates54

 Adverse events.....54

 Concomitant medications/medical histories56

Appendix IV: ADFACEVD Analysis Parameters.....56

Appendix V: External files used during ADaM dataset creation57

Appendix VI: Surveillance Times60

Appendix VII: Efficacy Flow Charts.....61

Appendix VIII: Detailed subsetting for Analysis:.....65

 1. Key Analysis Population Subsetting:65

 2. Adverse Event Analysis Reporting Period Subsetting:66

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

1. Introduction

1.1 Purpose

This document provides context for the analysis datasets and terminology that benefit from additional explanation beyond the Data Definition document (define.xml) for an individual study. In addition, this document provides a summary of ADaM conformance findings. This ADRG covers:

- Efficacy analyses for age group 12-15 years in blinded placebo-controlled follow-up
- Immunogenicity analysis for age groups 12-15 years vs 16-25 years from Dose 1 to 1 month after Dose 2
- Safety analysis for age groups 12-15 years vs 16-25 years
 - From Dose 1 to 1 month after Dose 2 for both age groups
 - From Dose 1 to cutoff date for 12-15 years age group
- Additional reference safety data analysis for 16-55 years age group
 - From Dose 1 to 1 month after Dose 2
 - From Dose 1 to unblinding date.

1.2 Acronyms

Acronym	Translation
ADaM	Analysis Dataset Model
ADRG	Analysis Data Reviewer's Guide
AE	Adverse Event
COVID-19	Coronavirus Disease 2019
eCRF	Electronic Case Report Form
eDT	Electronic Data Transfer (e.g. central lab data, ECG vendor data, PK data, etc.)
ICD	Informed Consent Document
IG	Implementation Guide
IWR	Interactive Web-based Response
LAR	Legally Acceptable Representative
LLOQ	Lower Limit of Quantification
MedDRA	Medical Dictionary for Regulatory Activities
modRNA	nucleoside-modified messenger ribonucleic acid
NA	Not Applicable
NAAT	nucleic acid amplification test
SAP	Statistical Analysis Plan
SDTM	Study Data Tabulation Model
SoA	Schedule of Activities
TAUG	Therapeutic Area User Guide
WHO	World Health Organization
VE	Vaccine Efficacy
WHO DDG	WHO Drug Dictionary Global
WOCBP	Women of childbearing potential

1.3 Study Data Standards and Dictionary Inventory

Standard or Dictionary	Versions Used
SDTM	<ul style="list-style-type: none"> •SDTM v1.4 •SDTM-IG v3.2
SDTM Controlled Terminology	CDISC SDTM Controlled Terminology, 2020-03-27
ADaM	<ul style="list-style-type: none"> •ADaM v2.1 •ADaM-IG v1.1
ADaM Controlled Terminology	CDISC ADaM Controlled Terminology, 2020-03-27
Data Definitions	Define-XML v2.0
Medications Dictionary	WHO DD GLOBALB3Mar2021
Medical Events Dictionary	MedDRA v23.1
Pinnacle 21	Pinnacle 21 Enterprise 4.1.4

1.4 Source Data Used for Analysis Dataset Creation

For analysis, a data cutoff of 13Mar2021 was applied on SDTM data. Furthermore, any data related to the booster portion of the Phase 1 subjects were also programmatically excluded from SDTM data.

The ADaM datasets for this study were derived from the SDTM datasets.

External files used during ADaM dataset creation are listed in [Appendix V](#).

2. Protocol Description

2.1 Protocol Number and Title

Protocol Number: C4591001

Protocol Short Title: A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals.

Note: Protocol Amendment's 13, 14 and beyond mentioned elsewhere in the submission documentation are out of scope for this sBLA and have not been included in this ADRG.

Protocol Versions:

Amendment 12: 2020-01-08

- Because of a formatting error in protocol amendment 11, exclusion criterion 4 was inadvertently added to exclusion criterion 3 and the subsequent criteria renumbered. This amendment corrects that error.

Amendment 11: 2020-01-04

- Added assessment of VE against asymptomatic infection vis N-binding antibody seroconversion and a potential intensive surveillance period for nasal swabbing, for assessment via NAAT:

- Corresponding SoA and procedures added

Amendment 10: 2020-12-01

- Added the possibility of administering BNT162b2 to participants who originally received placebo, following any local or national recommendations.
- Added the possibility of administering BNT162b2 to participants who originally received placebo, following completion of the active safety surveillance period.

Amendment 9: 2020-10-29

- To better align with the natural history of SARS-CoV-2 infection, added Phase 2/3 secondary efficacy objectives, estimands, and endpoints to include COVID-19 cases that occur from 14 days after the second dose; also modified the existing secondary efficacy objectives, estimands, and endpoints to include COVID-19 cases that occur from 14 days, as well as 7 days, after the second dose;
 - Made corresponding changes to the study design, study assessments and procedures, and statistical analysis sections.
- Clarified that interim analyses will be conducted after accrual of at least 62, 92, and 120 cases.
- Included any participants 16 through 17 years of age enrolled under this amendment in the reactogenicity subset.
- Clarified that serology data after a postbaseline positive SARS-CoV-2 test result will not be included in the analysis based on the evaluable immunogenicity populations.

Amendment 8: 2020-10-15

- Clarified that for participants who are not in the reactogenicity subset, local reactions and systemic events following vaccination should be detected and reported as AEs.
- Clarified that premenarchal females are not WOCBP.

Amendment 7: 2020-10-06

- Reduced the lower age range to include adolescents 12 to 15 years of age and added corresponding objectives.
- Added that 2 periods of potential COVID-19 symptoms within 4 days will be considered as a single illness.

Amendment 6: 2020-09-08

- Removed exclusion criterion 2 (i.e., known infection with HIV, HCV, or HBV) for Phase 3 and added criteria for HIV-positive participants.
- Decreased the lower age limit and removed the upper age limit for inclusion in Phase 2/3 in order to evaluate BNT162b2 30 µg in older adolescents and those over 85 years of age; updated the title and other references to adults to align with this change.
- Clarified that inclusion criterion 4 (i.e., participants at higher risk for acquiring COVID-19) is applicable for Phase 2/3 only, and provided some examples

Amendment 5: 2020-07-24

- Clarified that a single vaccine candidate, administered as 2 doses 21 days apart, will be studied in Phase 2/3.

Study C4591001

Analysis Data Reviewer's Guide

- Stated that the vaccine candidate selected for Phase 2/3 evaluation is BNT162b2 at a dose of 30 µg.
- Renamed Stage 1 to Phase 1, removed Stage 2, and renamed Stage 3 to Phase 2/3.
- Clarified which stopping rules apply to which phase of the study.
- Moved the immunogenicity objectives in Phase 2/3 to become exploratory.
- Modified exclusion criterion 5, so that participants with a previous clinical or microbiological diagnosis of COVID-19 are excluded from all phases of the study.

Amendment 4: 2020-06-30

- BNT162b3 candidate has been added to the protocol.
- Further nonclinical data are available to support the study of the BNT162b3 candidate in humans, and the candidate has been added to the protocol.
- The 6-month safety follow-up telephone contact has been changed to an in-person visit for Stage 3 participants, to allow collection of an immunogenicity blood sample.

Amendment 3: 2020-06-10

- 20-µg dose level is formally included for BNT162b1 and BNT162b2.
- In order to increase flexibility enrolling participants, an extended screening window (increased from 14 to 28 days) for sentinel participants in Stage 1 has been added. This is considered acceptable since eligible participants are expected to be either healthy or have stable medical conditions.

Amendment 2: 2020-05-27

- Added a 50-µg dose level for vaccine candidates based on the modRNA platform (ie, BNT162b1, BNT162b2, and BNT162b3).


Amendment 1: 2020-05-13

- Decreased the dose levels for BNT162a1 and BNT162c2
- Modified exclusion criteria and prohibited inhaled/nebulized corticosteroids for sentinel participants in Stage 1.

Original Protocol 2020-04-15

2.2 Protocol Design in Relation to ADaM Concepts

The study consists of 2 parts. Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part. These parts, and the progression between them, are detailed in the schema.



Abbreviation: IRC = internal review committee.

Note: Participants ≥ 16 years of age who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study.

The study will evaluate the safety, tolerability, and immunogenicity of 3 different SARS-CoV-2 RNA vaccine candidates against COVID-19 and the efficacy of 1 candidate:

- As a 2-dose (separated by 21 days) schedule;
- At various dose levels in Phase 1;
- In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12 years of age [stratified as 12-15, 16-55, or >55 years of age]).

The vaccine candidate selected for Phase 2/3 evaluation is BNT162b2 at a dose of 30 µg.

Phase 2/3 is event-driven. Under the assumption of a true VE rate of ≥60%, after the second dose of investigational product, a target of 164 primary-endpoint cases of confirmed COVID-19 due to SARS-CoV-2 occurring at least 7 days following the second dose of the primary series of the candidate vaccine will be sufficient to provide 90% power to conclude true VE >30% with high probability. The total number of participants enrolled in Phase 2/3 may vary depending on the incidence of COVID-19 at the time of the enrollment, the true underlying VE, and a potential early stop for efficacy or futility.

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

3. Analysis Considerations Related to Multiple Analysis Datasets

3.1 Study Populations and Core Variables

A description of the key analysis subject populations used in this study along with the subsetting criteria required to identify those subjects in each population from the ADaM datasets and the expected N associated with each analysis is described in detail in [Appendix VIII](#) Section 1.

Core variables are those that are represented across all/most analysis datasets.

Variable Type	Variable Name	Variable Description
Study/Site/ Subject ID variables	STUDYID	Study identifier used for this protocol
	USUBJID	Unique subject identifier
	SUBJID	Subject identifier for the study
	SITEID	Study site identifier
Demographics	AGE	Age at ICD
	AGETR01	Age at Dose 1
	AGEGR1	Pooled age group 1 (based on Age at Dose 1) Including following age categories: 12-15 Years; 16-55 Years; >55 Years for Phase 2/3 subjects. 18-55 Years; 65-85 Years for Phase 1 subjects.
	AGEGR1N	Pooled age group 1 (N): 1= 12-15 Years; 2= 16-55 Years; 3= 18-55 Years; 4= 65-85 Years; 5= >55 Years
	AGEGR4	Pooled age group 4 (based on Age at Dose 1, For 12 to 25 years of age for safety and noninferiority assessment) Including following age categories: 12-15 Years; 16-25 Years
	AGEGR4N	Pooled age group 4 (N): 1= 12-15 Years; 2= 16-25 Years
	SEX	Sex: F=Female; M=Male
	ETHNIC	Ethnicity, Including HISPANIC OR LATINO; NOT HISPANIC OR LATINO; NOT REPORTED
	RACE	Race, including WHITE; BLACK OR AFRICAN AMERICAN; ASIAN; MULTIPLE; NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER; OTHER; NOT REPORTED
Baseline Status	COVBLST	Baseline SARS-CoV-2 status: Positive or Negative
	HIVFL	HIV positive subjects Flag
Treatment Variables	ARM	Description of Planned Arm
	ARMCD	Planned Arm Code
	ACTARM	Description of Actual Arm
	ACTARMCD	Actual Arm Code
	TRTSDTM	Datetime of first exposure to treatment
	TRTEDTM	Datetime of last exposure to treatment
	TR01SDTM	Datetime of first exposure to treatment for blinded

Variable Type	Variable Name	Variable Description
		placebo-controlled period
	TR01EDTM	Datetime of last exposure to treatment for blinded placebo-controlled period
	TR02SDTM	Datetime of first exposure to treatment for open label vaccination period
	TR02EDTM	Datetime of last exposure to treatment for open label vaccination period
	TRT01A	Actual Treatment for blinded placebo-controlled period
	TRT01AN	Actual Treatment for blinded placebo-controlled period (N)
	TRT01P	Planned Treatment for blinded placebo-controlled period
	TRT01PN	Planned Treatment for blinded placebo-controlled period (N)
	TRT02A	Actual Treatment for open label vaccination period
	TRT02AN	Actual Treatment for open label vaccination period (N)
	TRT02P	Planned Treatment for open label vaccination period
	TRT02PN	Planned Treatment for open label vaccination period (N)
	VAX101	Actual vaccination taken at Dose 1 for blinded placebo-controlled period
	VAX102	Actual vaccination taken at Dose 2 for blinded placebo-controlled period
	VAX10U	Actual vaccination taken at unplanned dose for blinded placebo-controlled period
	VAX201	Actual vaccination taken at Dose 1 for open label vaccination period
	VAX202	Actual vaccination taken at Dose 2 for open label vaccination period
	VAX20U	Actual vaccination taken at unplanned dose for open label vaccination period
	VAX101DT	Date of Dose 1 for blinded placebo-controlled period
	VAX102DT	Date of Dose 2 for blinded placebo-controlled period
	VAX10UDT	Date of unplanned dose for blinded placebo-controlled period
	VAX201DT	Date of Dose 1 for open label vaccination period
	VAX202DT	Date of Dose 2 for open label vaccination period
	VAX20UDT	Date of unplanned dose for open label vaccination period
Study Phase	PHASE	Study Phase "Phase 1" for subjects from Phase 1; "Phase 2_ds360/ds6000" for subjects from Phase 2; "Phase 3_ds6000" for subjects from Phase 3 and

Variable Type	Variable Name	Variable Description
		<p>included in DS6000; "Phase 3" for other subjects from Phase 3</p> <p>DS360 indicates 360 Phase 2 subjects. DS6000 indicates first 6000 subjects from Phase 3 with 3000 subjects receiving actual treatment, and 3000 subjects receiving placebo. See more details in Appendix V</p>
	PHASEN	<p>Study phase (N). 1= Phase 1; 2 = Phase 2_ds360/ds6000; 3= Phase 3_ds6000; 4= Phase 3</p>
Date/Time variables	UNBLNDDT	<p>Treatment unblinding date This is the start date of open-label follow up/vaccination period for subjects who were unblinded</p>
	BDCSRDT	<p>Censor date for blinded placebo-controlled follow up period. This date is the earliest date of the day before treatment unblinding date UNBLNDDT (if applicable), the day before first dose date of BNT162b2 at open label vaccination period (if applicable), end of study date (if applicable), complete of study date (if applicable) and the date of cutoff (13Mar2021). This date is used for AE incidence rate summary table (Exposure adjusted) for blinded placebo-controlled follow up period.</p>
	X1CSRDT	<p>Censor date for open label follow up period. This date is the earliest date of end of study date (if applicable), complete of study date (if applicable) and the date of cutoff (13Mar2021). This date is used for AE incidence rate summary table for open label follow up period.</p>
Population Flags**	DS3KFL	<p>Flag of phase2/3 subjects with at least 6 months of follow-up time after Dose 2 (28*6=168 days after Dose 2 by the date of cutoff) for subjects originally received BNT162b2. This flag is used to subset the subjects for AE summary tables with reporting period from Dose 1 to 6-month after Dose 2 regardless of unblinding or not. There are 12006 subjects in total from safety population who had at least 6 months follow-up after Dose 2, excluding the subjects with multiple sites.</p>
	MULENRFL	<p>Subjects enrolled in multiple sites are excluded from all analysis. Note: Subjects flagged as YES-POP4 in variable SUPPDV.QNAM = "CAPE" are the subjects with multiple sites and were excluded</p>

Variable Type	Variable Name	Variable Description
		from all of summary analysis.
	REACTOFL	Population flag for subjects in reactogenicity subset
	PEDIMMFL	Population flag for 12-15/16-25 years of age subjects in immunogenicity subset (280 subjects from active group and 50 subjects from placebo group for each age group) . These 660 subjects were randomly selected for immunobridging assessment.
	PEDREAFL	Population flag for 12-15/16-25 years of age reactogenicity subset
	EV1MD2FL	Population flag for subjects without evidence of infection up to 1 Month After Dose 2
	ENRFL	Enrolled population flag defined as: All participants who have a signed ICD.
	RANDFL	Randomized population flag defined as: All participants who are assigned a randomization number in the IWR system.
	RAND1FL	Randomized population by excluding the subjects enrolled at multiple sites
	SAFFL	Safety population flag defined as: All randomized participants who receive at least 1 dose of the study intervention. Analyses of reactogenicity endpoints will be based on a subset of the safety population that includes participants with any e-diary data reported after vaccination Note: Subjects flagged as both YES-POP1 and YES-POP5 in variable SUPPDV.QNAM = "CAPE" were excluded from safety population for unreliable data due to lack of principal investigator oversight.
	SAF1FL	Safety population after excluding subjects enrolled at multiple sites, HIV positive subjects and subjects with all doses indeterminate
	SAF2FL	Safety population after excluding subjects enrolled at multiple sites and subjects with all doses indeterminate
	AAI01FL	Dose 1 all-available Immunogenicity Population Flag defined as: For Phase 1 only: all randomized participants who receive at least 1 dose of the study intervention with at least 1 valid and determinate immunogenicity result after Dose 1 but before Dose 2.
	AAI02FL	Dose 2 all-available Immunogenicity Population Flag defined as: All randomized participants who receive at least 1

Variable Type	Variable Name	Variable Description
		<p>dose of the study intervention with at least 1 valid and determinate immunogenicity result after Dose 2.</p> <p>Note: Subjects flagged as YES-POP5 in variable SUPPDV.QNAM = "CAPE" were excluded from all-available immunogenicity population for unreliable data due to lack of principal investigator oversight.</p>
	EVAL01FL	<p>Dose 1 evaluable Immunogenicity Population Flag defined as:</p> <p>For Phase 1 only, all eligible randomized participants who receive the vaccine to which they are randomly assigned at the first dose, have at least 1 valid and determinate immunogenicity result from the blood collection within an appropriate window after Dose 1 (same as visit window, ie, within 19-23 days after Dose 1), and have no other important protocol deviations as determined by the clinician.</p>
	EVAL02FL	<p>Dose 2 evaluable Immunogenicity Population Flag defined as:</p> <p>All eligible randomized participants who receive 2 doses of the vaccine to which they are randomly assigned, with Dose 2 received within the predefined window (within 19-42 days after Dose 1), have at least 1 valid and determinate immunogenicity result after Dose 2 from the blood collection within an appropriate window after Dose 2 (within 6-8 days after Dose 2 for Phase 1 and within 28-42 days after Dose 2 for Phase 2/3), and have no other important protocol deviations as determined by the clinician.</p> <p>Note: Subjects flagged as YES-POP3 in variable SUPPDV.QNAM = "CAPE" were excluded from evaluable immunogenicity population due to important protocol deviation identified by clinical.</p>
	AAI1EFFL	<p>Dose 1 all-available efficacy population flag defined as:</p> <p>All randomized participants who receive at least 1 vaccination.</p> <p>Used for efficacy analysis.</p> <p>Note: Subjects flagged as YES-POP5 in variable SUPPDV.QNAM = "CAPE" were excluded from all-available efficacy population for unreliable data due to lack of principal investigator oversight.</p>
	AAI2EFFL	<p>Dose 2 all-available efficacy population flag defined as:</p> <p>All randomized participants who complete</p>

Variable Type	Variable Name	Variable Description
		2 vaccination doses. Used for efficacy analysis. Note: Subjects flagged as YES-POP5 in variable SUPPDV.QNAM = "CAPE" were excluded from all-available efficacy population for unreliable data due to lack of principal investigator oversight.
	EVALEFFL	Evaluable efficacy population flag (7 days) defined as: All eligible randomized participants who receive all vaccination(s) as randomized, with Dose 2 received within the predefined window (within 19-42 days after Dose 1) and have no other important protocol deviations as determined by the clinician on or before 7 days after Dose 2. Used for efficacy analysis. Note: Subjects flagged as YES-POP2 in variable SUPPDV.QNAM = "CAPE" were excluded from evaluable efficacy population due to important protocol deviation identified by clinical.

**See [Appendix VIII](#) for additional variables used when subsetting data for each analysis.

3.2 Treatment Variable

ARM versus TRTxxP

Are the values of ARM equivalent in meaning to values of TRTxxP?

No, TRT01P is null when ARM equals to "NOT ASSIGNED" or "SCREEN FAILURE". ARM represents the planned arm for the blinded placebo-controlled period based on randomization file. TRT01P has the planned treatment for the blinded placebo-controlled period. TRT02P has the planned treatments of open label vaccination period for subjects who received placebo only in the blinded placebo-controlled period and become eligible for receipt of BNT162b2 after unblinding. See details in below table.

PHASE	ARM	TRT01P	TRT02P
Phase 1	BNT162b1 Phase 1 (10 mcg)	BNT162b1 Phase 1 (10 mcg)	-
	BNT162b1 Phase 1 (20 mcg)	BNT162b1 Phase 1 (20 mcg)	-
	BNT162b1 Phase 1 (30 mcg)	BNT162b1 Phase 1 (30 mcg)	-
	BNT162b1 Phase 1 (100/10 mcg)	BNT162b1 Phase 1 (100/10 mcg)	-
	BNT162b2 Phase 1 (10 mcg)	BNT162b2 Phase 1 (10 mcg)	-
	BNT162b2 Phase 1 (20 mcg)	BNT162b2 Phase 1 (20 mcg)	-
	BNT162b2 Phase 1 (30 mcg)	BNT162b2 Phase 1 (30 mcg)	-

PHASE	ARM	TRT01P	TRT02P
	Placebo	Placebo	-
	Placebo	Placebo	BNT162b2 Phase 1 (30 mcg)
	NOT ASSIGNED	-	-
	SCREEN FAILURE	-	-
Phase 2/3	BNT162b2 Phase 2/3 (30 mcg)	BNT162b2 Phase 2/3 (30 mcg)	-
	Placebo	Placebo	-
	Placebo	Placebo	BNT162b2 Phase 2/3 (30 mcg)
	NOT ASSIGNED	-	-
	SCREEN FAILURE	-	-

Note: Unit of dose 'mcg' was displayed as 'µg' in all of outputs.

ACTARM versus TRTxxA

If TRTxxA is used, then are the values of ACTARM equivalent in meaning to values of TRT01A?

No, ACTARM represents the actual arm for the blinded placebo-controlled period. TRT01A has the actual treatment for the blinded placebo-controlled period, TRT02A has the actual treatment of open label vaccination period for subjects who received placebo only in the blinded placebo-controlled period and received BNT162b2 after unblinding. See details in below table.

PHASE	ACTARM	TRT01A	TRT02A
Phase 1	BNT162b1 Phase 1 (10 mcg)	BNT162b1 Phase 1 (10 mcg)	-
	BNT162b1 Phase 1 (20 mcg)	BNT162b1 Phase 1 (20 mcg)	-
	BNT162b1 Phase 1 (30 mcg)	BNT162b1 Phase 1 (30 mcg)	-
	BNT162b1 Phase 1 (100/10 mcg)	BNT162b1 Phase 1 (100/10 mcg)	-
	BNT162b2 Phase 1 (10 mcg)	BNT162b2 Phase 1 (10 mcg)	-
	BNT162b2 Phase 1 (20 mcg)	BNT162b2 Phase 1 (20 mcg)	-
	BNT162b2 Phase 1 (30 mcg)	BNT162b2 Phase 1 (30 mcg)	-
	Placebo	Placebo	-
	Placebo	Placebo	BNT162b2 Phase 1 (30 mcg)
	NOT ASSIGNED	-	-
	SCREEN FAILURE	-	-
Phase 2/3	BNT162b2 Phase 2/3 (30 mcg)	BNT162b2 Phase 2/3 (30 mcg)	-
	Placebo	Placebo	-
	Placebo	Placebo	BNT162b2 Phase 2/3 (30 mcg)
	Not Treated	-	-
	SCREEN FAILURE	-	-

Note: Unit of dose 'mcg' was displayed as 'µg' in all of outputs.

Are both planned and actual treatment variables used in analyses?

Yes. Both actual treatment and planned treatment were used in the analysis. Planned treatment variable was used across efficacy analysis, immunogenicity analysis and disposition table. Actual treatment variable was used across safety analysis.

See details in below table.

Reporting Period	Analysis Population	Treatment Variables Used in Analysis	Applicable analysis
Blinded placebo-controlled period or Open label follow-up period	Safety	TRT01A	Conduct of study, Adverse Event, Medical History, Concomitant Medications/Vaccinations, Reactogenicity
	Randomized	TRT01P	Vaccine as Administered, Disposition, Immunogenicity, efficacy
Open label follow-up period (For subjects who received placebo only in the blinded placebo-controlled period and then received BNT162b2 after unblinding)	Safety	TRT02A	Adverse Event

Note: Unit of dose ‘mcg’ was displayed as ‘µg’ in all of outputs.

Use of ADaM Treatment Grouping Variables in Analysis

Are both planned and actual treatment grouping variables used in analysis?

No. Neither planned nor actual treatment grouping variables are used in analysis

3.3 Subject Issues that Require Special Analysis Rules

- Subjects whose data is considered potentially unreliable due to lack of PI oversight identified as significant quality event were excluded from analysis populations.
- According to the Protocol, HIV-positive subjects in Phase 3 will not be included in analyses of the overall study objectives, with the exception of the specific exploratory objective for this group. In the sBLA, Human immunodeficiency virus (HIV)-positive subjects are included in the analysis populations the summary of analysis populations and shown as part of the study demographics and study conduct tables but not included in the analyses of overall safety, immunogenicity and efficacy endpoints.

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

- Handling of Misallocation of Vaccine:
 - For AE summaries, demographics and all other tables by safety population, count the subjects in active treatment group as long as one of the doses is active vaccination BNT162b2.
 - For reactogenicity analyses by dose, subjects who received a different investigational product regimen from the regimen they were assigned will be included in the safety population for the summaries of individual vaccinations up until the point their regimen differs from the assigned regimen, at which point they would no longer be included.
 - Immediate AE and AEs post dose 1 and 2 were summarized by following the same rule as reactogenicity for post dose 1 and post dose 2 summary.

The following table shows how subjects are assigned to treatment arms for safety related analyses under all possible vaccination scenarios:

Scenario	Vaccine Dose		Actual Arm (Overall)	Analysis					
	Actual Dose 1	Actual Dose 2		Reactoge- nicity Post Dose 1	Reactoge- nicity Post Dose 2	Reactoge- nicity post any Dose	AE Post Dose 1	AE Post Dose 2	Other*
1	Active	Active	Active	Active	Active	Active	Active	Active	Active
2	Placebo	Placebo	Placebo	Placebo	Placebo	Placebo	Placebo	Placebo	Placebo
3	Active		Active	Active	<i>Exclude</i>	Active	Active	<i>Exclude</i>	Active
4	Placebo		Placebo	Placebo	<i>Exclude</i>	Placebo	Placebo	<i>Exclude</i>	Placebo
5	Active	Placebo	Active	Active	<i>Exclude</i>	Active	Active	<i>Exclude</i>	Active
6	Placebo	Active	Active	Placebo	<i>Exclude</i>	Active	Placebo	<i>Exclude</i>	Active

* Other includes all other AE summary, demographic, and other study conduct tables by Safety Population (Follow Overall Actual Arm)

- 6 Subjects were enrolled into the study more than once resulting in significant misconduct and compromising the integrity of the study data. These subjects will not be included in any analyses and will only be included in separate listings (disposition listing, AE listing, local reaction listing and systemic events listing) created specifically for this subject. These subjects will be excluded from other outputs using the exclusion flag (MULENRFL) in ADSL.

Duplicated Subject #	SUBJID at 1 st Site	SUBJID at 2 nd site
1	10561101	11331382
2	11101123	11331405
3	11491117	12691090
4	12691070	11351357
5	11341006	10891112
6	11231105	10711213

- Subjects C4591001 1163 11631006, C4591001 1163 11631005, C4591001 1163 11631008, are vaccinated as per CRF, but due to lack of matching actual vaccination data, these are not assigned to any dosing group. In the analyses these subjects will be:

For safety:

- a. Excluded from all table/figures.
- b. Included in all regular listings.

For efficacy:

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

- a. Excluded from the evaluable population by the definition in the SAP, because it is not possible to confirm if they received the vaccination as randomized.
- b. Included in all tables/figures/listings based on all-available population.

3.4 Use of Visit Windowing, Unscheduled Visits, and Record Selection

Was windowing used in one or more analysis datasets?

Yes, windowing was considered during the derivation of ADAE.VPHASE. Please refer to [Appendix II](#) for more details.

Were unscheduled visits used in any analyses?

Yes, please refer to Section [5.2.7](#) and [5.2.9](#) for more details.

Based on protocol guidance, multiple unscheduled Covid illness visits that are less than four days apart are collapsed in ADSYMPT into their respective earlier visit/s and are considered as single unscheduled illness visit during the analysis.

3.5 Imputation/Derivation Methods

If date imputation was performed, were there rules that were used in multiple analysis datasets?

Yes, date imputations for partial or missing dates were performed for adverse events, medical history and concomitant medication described in [Appendix III](#).

Was DTYPE used in one or more analysis datasets?

Yes, DTYPE was used in ADFACEVD and ADVA. For details on DTYPE, please refer to Section [5.2.7](#) and [5.2.11](#).

4. Analysis Data Creation and Processing Issues

4.1 Split Datasets

There are no split datasets.

4.2 Data Dependencies

All datasets pull core variable values from ADSL. ADC19EF also uses the ADSYMPT dataset as an input to create efficacy parameter variables.

4.3 Intermediate Datasets

No intermediate analysis datasets were created in this trial.

5. Analysis Dataset Descriptions

5.1 Overview

Are data for screen failures, including data for run-in screening (for example, SDTM values of ARMCD='SCRNFAIL', or 'NOTASSGN') included in ADaM datasets?

Yes. Subjects with 'NOTASSGN' 'SCRNFAIL' are included in ADSL, ADAE, ADCM,

Are data taken from an ongoing study?

Yes. All data up through 13Mar2021 cutoff are included in the SDTM datasets and used for ADaM datasets and analyses. Furthermore, any data related to the booster portion of the Phase 1 subjects was also programmatically excluded from SDTM data.

Do the analysis datasets support all protocol- and statistical analysis plan-specified objectives?

No. Objectives on VE against asymptomatic infection and Phase 1 booster are not assessed. The booster and variant strain assessment in Protocol amendment 14 and SAP V5 are also not included.

Additional Content of Interest

No additional content of Interest.

5.2 Analysis Datasets

Dataset Label	Class	Efficacy	Safety	Baseline or other subject PK/PD	Primary	Structure
ADSL Subject-Level Analysis Dataset	SUBJECT LEVEL ANALYSIS DATASET			X		One record per subject
ADAE Adverse Events Analysis Dataset	OCCURRENCE DATA STRUCTURE		X		X	One record or multiple records per subject per adverse event per event start date
ADCEVD Diary and CRF Event Analysis Dataset	OCCURRENCE DATA STRUCTURE		X			One record or multiple records per subject per clinical event
ADFACEVD Diary and Non-event Analysis Dataset	BASIC DATA STRUCTURE		X		X	One record or multiple records per subject per analysis parameter per analysis timepoint
ADCM Concomitant Medications Analysis Dataset	OCCURRENCE DATA STRUCTURE		X			One record or multiple records per subject per recorded medication occurrence or constant-dosing interval

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

Dataset Label	Class	Efficacy	Safety	Baseline or other subject PK/PD	Primary	Structure
ADDS Disposition Analysis Dataset	OCCURRENCE DATA STRUCTURE			X		One record or multiple records per subject per disposition status or protocol milestone
ADDV Protocol Deviation Analysis Dataset	OCCURRENCE DATA STRUCTURE			X		One record or multiple records per subject per protocol deviation per event start date
ADMH Medical History Analysis Dataset	OCCURRENCE DATA STRUCTURE			X		One record or multiple records per subject per medical history event
ADC19EF Covid-19 Efficacy Analysis	BASIC DATA STRUCTURE	X			X	One record or multiple records per subject per analysis parameter per analysis timepoint
ADSYMPT Covid-19 Signs and Symptoms	BASIC DATA STRUCTURE	X			X	One record or multiple records per subject per analysis parameter per analysis timepoint
ADVA Immunogenicity Analysis Dataset	BASIC DATA STRUCTURE	X				One record or multiple records per subject per analysis parameter per analysis visit

5.2.1 ADSL – Subject-Level Analysis Dataset

ADSL included all subjects in the DM domain and contained relevant subject level information, treatment variables and analysis set flags. This dataset supported the creation of all other analysis datasets. ADSL also comprised the variables to support baseline characteristics and disposition analyses, and the classification variables used for subgroup analyses and used as covariates for statistical analyses.

ADSL includes the following information for each subject:

- Subject identifier
- Demographic information
- Planned treatment and actual treatment (details described in [Section 3.1](#) Core Variables)
- Population flags (details described in [Section 3.1](#) Core Variables)
- Key dates and datetime related to conduct of study (details described in [Section 3.1](#) Core Variables)
- Variables to support subgroup analyses
 - Age group (details described in [Section 3.1](#) Core Variables for Age group)
 - Sex (Female and Male)

- Race (White, Black or African American and All Others)
 - Note: All Others = American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, multiracial, and not reported race categories.
- Ethnicity (Hispanic/Latino, Non-Hispanic/Non-Latino and Not Reported)
- Baseline SARS-CoV-2 Status (Positive and Negative)
- Flag for Comorbidities (Y/N)
- Obese Flag for Adolescent (Y/N)

5.2.2 ADCEVD – Diary and CRF Event Analysis Dataset

This dataset contains information on duration of local reactions (LR: redness, swelling, and pain at the injection site) and systemic events (SE: fever, chills, diarrhea, fatigue, headache, joint pain, muscle pain and vomiting) and is used to generate the summaries of duration of these reactions or events.

Duration of each reaction or event is defined as the number of days from the start of the first reported event to the resolution of the last reported event ($ADURN = AENDT - ASTDT + 1$), which is the sum of the duration of the reactogenicity event in the assessment period and beyond the assessment period if a reactogenicity event continued beyond the assessment interval. Those clinical assessments at unscheduled visits within 7 days after each dose were involved in the derivation of duration and summary analysis.

No imputation was carried out for partial or missing symptom resolved dates from investigator data collected on the CRF. Those events with the resolution date partial or missing ($AENDT$ eq missing), were included in the “Unknown” category for any reporting. However, if a reaction is ongoing at the time of a subsequent vaccination, the end date/day for the ongoing reaction would be the date/day that the next vaccine is administered, which will be used for the duration computation. Participants with no reported reaction have no duration.

5.2.3 ADAE – Adverse Events Analysis Dataset

This is the main safety analysis dataset comprised of adverse events recorded on the CRF. For dictionary coding, MedDRA version 23.1 was used. Partial start dates or partial end dates of adverse events were imputed using rules described in [Appendix III](#).

AE data is reported excluding the reactogenicity events [$AECAT$ not in (“REACTOGENICITY”)]. AE summaries were analyzed based on the specific reporting periods. The vaccine phase (VPHASE) was derived based on the start date of the AE and the phase date ($ADSL.V01DT$, $ADSL.V02DT$, $ADSL.V02OBDT$, $ADSL.V03DT$, $ADSL.V04DT$), please refer to [Appendix II](#) for more details, and was applied to select AEs for summaries based on different reporting period. See details in [Appendix VIII](#).

5.2.4 ADCM – Concomitant Medications Analysis Dataset

The dataset contains information of nonstudy vaccines ($CMCAT = “VACCINATIONS”$), concomitant medications ($CMCAT = “GENERAL CONCOMITANT MEDICATIONS”$) and prohibited concomitant medications ($CMCAT$ in (‘ CONCOMITANT IMMUNOSUPPRESSIVE THERAPY’, ‘ CORTICOSTEROIDS’, ‘ IMMUNOGLOBULINS’)). For dictionary coding, WHODD GLOBALB3Mar2021 were used.

Partial start dates or partial end dates of nonstudy vaccines and concomitant medications were

5.2.5 ADDS – Disposition Analysis Dataset

This dataset contains information for various disposition events (DSCAT = “DISPOSITION EVENT”) for each subject throughout the study. The phases in the disposition event are presented in the table below as DSPHASE. The subject's completion status or reason for discontinuation is identified in DSDECOD (Standardized Disposition Term).

Disposition phases included in this study are as follows:

DSCAT	DSPHASE
DISPOSITION EVENT	SCREENING
DISPOSITION EVENT	REPEAT SCREENING 1
DISPOSITION EVENT	VACCINATION
DISPOSITION EVENT	OPEN LABEL TREATMENT
DISPOSITION EVENT	FOLLOW-UP

5.2.6 ADDV – Protocol Deviation Analysis Dataset

This dataset contains information about protocol deviation events and causes for protocol deviations. Important protocol deviations were flagged as “Important” in variable DVCAT and the corresponding exclusion flag was capture in SUPPDV.QNAM='CAPE'.

5.2.7 ADFACEVD – Diary and Non-event Analysis Dataset

This is a primary analysis dataset for vaccine studies, including information of occurrence, severity level and maximum severity of reactogenicity assessments reported in the e-diary. Reactogenicity assessments cover 3 parts: local reactions, systemic events and use of antipyretic/pain medication which were assessed within 7 days after each dose.

ADFACEVD is a dataset using BDS structure, which contains one or multiple records per subject per analysis parameter (PARAM) per analysis timepoint (ATPT). Variables PARAM and PARAMCD were used to distinguish different measurements or findings. The detailed list of parameters included in this dataset are described in [Appendix IV](#).

Unscheduled visits of clinical assessments within 7 days after each vaccination for reactogenicity from FACE and VS dataset were considered for summary analysis.

Reactogenicity assessments reported in the e-diary on or after the date of treatment unblinding (ADSL.UNBLNDDT) were excluded from onset and maximum severity summary analysis. However events with onset before unblinding that continue after the date of unblinding were used in duration calculation. The events reported on the same day of unblinding were flagged as ‘Y’ in variable CUTUNBFL in ADFACEVD.

Maximum severity records were created in this dataset with DTYPE equal to "MAXIMUM". For all subjects, each local reaction or systemic event was targeted to have 7 assessments from Day 1 to Day 7. The maximum severity value reported during the interval was stored in an additional record with DTYPE equaled “MAXIMUM” (see the table as below) which is then used to summarize the maximum severity of these events.

PARAM	DTYPE
Redness maximum severity	MAXIMUM
Redness maximum diameter	MAXIMUM
Swelling maximum severity	MAXIMUM
Swelling maximum diameter	MAXIMUM
Pain at injection site maximum severity	MAXIMUM
Chills maximum severity	MAXIMUM
Diarrhea maximum severity	MAXIMUM
Fatigue maximum severity	MAXIMUM
Fever maximum temperature	MAXIMUM
Headache maximum severity	MAXIMUM
Joint pain maximum severity	MAXIMUM
Muscle pain maximum severity	MAXIMUM
Vomiting maximum severity	MAXIMUM

ADFACEVD includes the following key flags to support reactogenicity analyses:

- KNOWVFL – Y for that reaction or event if a subject had at least one record reported from day 1 to day 7 after each dose for a given reaction or event. This was derived per subject per dose per parameter(/event).
- EVENTFL – Y for that reaction or event if a subject had at least one record where the event occurred (where diameter>2.0 cm for redness and swelling or 38 °C<=temperature<=42 °C for fever or presence=yes for other symptoms) from day 1 to day 7 after each dose for a given reaction or event. This was derived per subject per dose per parameter(/event).
- KNOWVDFL – Y for a valid record (where the event was reported regardless if it occurred or not) at that day from day 1 to day 7 after each dose for a given reaction or event. This was derived per subject per dose per parameter(/event) per day.
- EVENTDFL – Y for a record where the event occurred (where diameter>2.0 cm for redness and swelling or 38 °C<=temperature<=42 °C for fever or with any valid severity/intensity or presence=yes for other symptoms) at that day from day 1 to day 7 after each dose. This was derived per subject per dose per parameter(/event) per day.

- Category variables FTEMCATN / FTEMCAT were used for fever summary analyses:

FTEMCATN	FTEMCAT
.	Missing
0	<38.0°C
1	≥38.0°C to 38.4°C
2	>38.4°C to 38.9°C
3	>38.9°C to 40.0°C
4	>40.0°C

- AVALCA1N / AVALCAT1 was derived based on diameter value and for parameters “Redness maximum severity” and “Swelling maximum severity” the maximum severity was derived per below table.

AVALCA1N	AVALCAT1	SEVERITY
0	>0-2.0	NONE
1	>2.0-5.0	MILD
2	>5.0-10.0	MODERATE
3	>10.0	SEVERE

5.2.8 ADMH – Medical History Analysis Dataset

This dataset contains all medical histories (MHCAT = “GENERAL MEDICAL HISTORY”) collected on the CRF. MedDRA version 23.1 was used for dictionary coding of medical histories. Partial start dates or partial end dates medical histories were imputed using rules described in [Appendix III](#).

5.2.9 ADSYMPT – Covid-19 Signs and Symptoms

The purpose of this dataset is to gather all signs/symptoms/conditions/laboratory results associated with SARS-CoV-2 from unscheduled Covid illness visits which will then be used to create the efficacy endpoint dataset ADC19EF. The main SDTM domains that were used to create the ADSYMPT dataset were CE, CM, DD, DS, HO, FA, IS, LB, MB, MH, PR, VS and the analysis dataset ADSL. Some of the important variables that make up this dataset are PARAMCD, PARAM, PARAMN, PARCAT1, PARCAT2, AVAL, AVALC, ADT, ASTDT, AENDT, VSSTRESU, MBMETHOD and ISMETHOD. Algorithms used to create each of these variables are included in the define.xml.

Protocol defined symptoms include “Chills, Diarrhea, Fever, New loss of taste or smell, New or increased cough, New or increased muscle pain, New or increased sore throat, Vomiting, Loss of taste/smell”.

These data were identified and captured in the ADSYMPT dataset as follows:

- From FA all records with FACAT = “EFFICACY” and FASCAT = “RESPIRATORY ILLNESS” provides the COVID-19 signs and symptoms.
- Subjects with local lab swab samples are identified using MB.MBTESTCD= "SARSCOV2" and MB.MBMETHOD = "IMMUNOCHROMATOGRAPHY".
- Subjects with central swab samples are identified using MB.MBTESTCD = "RTCOV2NS" and MB.MBMETHOD = "REVERSE TRANSCRIPTASE PCR".
- For the severe COVID-19 data from vital signs, subjects with admission to ICU, deaths, lab oxygenation data, ECG/oxygen therapy/intubation, etc., please refer to SAP Appendix 3 for more details

All COVID-19 signs, symptoms and conditions were defined as shown in the table below.

PARAMN	PARAMCD	PARAM	Derivation
1	CHILLS	CHILLS	Set to FA.FAOBJ when upcase(FA.FAOBJ) = "CHILLS" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
2	DIARRHEA	DIARRHEA	Set to FA.FAOBJ when upcase(FA.FAOBJ) = "DIARRHEA" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".

PARAMN	PARAMCD	PARAM	Derivation
3	FEVER	FEVER	Set to FA.FAOBJ when upcase(FA.FAOBJ) = "FEVER" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
4	NLTSTSM	NEW LOSS OF TASTE OR SMELL	Set to FA.FAOBJ when upcase(FA.FAOBJ) = "NEW LOSS OF TASTE OR SMELL" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
5	NCOUG	NEW OR INCREASED COUGH	Set to FA.FAOBJ when upcase(FA.FAOBJ) = "NEW OR INCREASED COUGH" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
6	NMUSPN	NEW OR INCREASED MUSCLE PAIN	Set to FA.FAOBJ when upcase(FA.FAOBJ) = "NEW OR INCREASED MUSCLE PAIN" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
7	NSTBRTH	NEW OR INCREASED SHORTNESS OF BREATH	Set to FA.FAOBJ when upcase(FA.FAOBJ) = "NEW OR INCREASED SHORTNESS OF BREATH" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
8	NSRTHROT	NEW OR INCREASED SORE THROAT	Set to FA.FAOBJ when upcase(FA.FAOBJ) = "NEW OR INCREASED SORE THROAT" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
9	VOMIT	VOMITING	Set to FA.FAOBJ when upcase(FA.FAOBJ) = "VOMITING" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
11	NNSLCONG	NEW OR INCREASED NASAL CONGESTION	Set to "NEW OR INCREASED NASAL CONGESTION" when upcase(FA.FAOBJ) = "NEW OR INCREASED NASAL CONGESTION" or "NASAL CONGESTION" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
14	WHEEZ	NEW OR INCREASED WHEEZING	Set to "NEW OR INCREASED WHEEZING" when upcase(FA.FAOBJ) = "NEW OR INCREASED WHEEZING" or upcase(FA.FAOBJ) = "WHEEZING" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
15	FATIGUE	FATIGUE	Set to FA.FAOBJ when upcase(FA.FAOBJ) = "FATIGUE" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
16	HEADACHE	HEADACHE	Set to FA.FAOBJ when upcase(FA.FAOBJ) = "HEADACHE" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".

PARAMN	PARAMCD	PARAM	Derivation
17	RIHNRA	RHINORRHOEA	Set to "RHINORRHOEA" when upcase(FA.FAOBJ) contains "RUNNY NOSE" or upcase(FA.FAOBJ) = "RHINORRHOEA" and FA.FAOBJ ^= "NEW OR INCREASED NASAL DISCHARGE" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
18	NAUSEA	NAUSEA	Set to FA.FAOBJ when upcase(FA.FAOBJ) = "NAUSEA" and FA.FACAT = "EFFICACY" and FA.FASCAT = "RESPIRATORY ILLNESS".
25	SARDFN	SIGNIFICANT ACUTE RENAL DYSFUNCTION	Set to CE.CESCAT when CE.CESCAT = "SIGNIFICANT ACUTE RENAL DYSFUNCTION".
30	SAHDFN	SIGNIFICANT ACUTE HEPATIC DYSFUNCTION	Set to CE.CESCAT when CE.CESCAT = "SIGNIFICANT ACUTE HEPATIC DYSFUNCTION".
35	SANDFN	SIGNIFICANT ACUTE NEUROLOGIC DYSFUNCTION	Set to CE.CESCAT when CE.CESCAT = "SIGNIFICANT ACUTE NEUROLOGIC DYSFUNCTION".
40	SARSCOV2	SEVERE ACUTE RESP SYNDROME CORONAVIRUS 2	Set to MB.MBTEST when upcase(MB.MBTESTCD) = "SARSCOV2" and MB.MBMETHOD = "IMMUNOCHROMATOGRAPHY".
41	RTC0V2NS	CEPHEID RT-PCR ASSAY FOR SARS-COV-2	Set to MB.MBTEST when upcase(MB.MBTESTCD) = "RTC0V2NS" and MB.MBMETHOD = "REVERSE TRANSCRIPTASE PCR".
50	RESP	RESPIRATORY RATE	Set to VS.VSTEST when VS.VSTESTCD = "RESP".
51	HR	HEART RATE	Set to VS.VSTEST when VS.VSTESTCD = "HR".
52	OXYSAT	OXYGEN SATURATION	Set to VS.VSTEST when VS.VSTESTCD = "OXYSAT".
53	DIABP	DIASTOLIC BLOOD PRESSURE	Set to VS.VSTEST when VS.VSTESTCD = "DIABP".
54	SYSBP	SYSTOLIC BLOOD PRESSURE	Set to VS.VSTEST when VS.VSTESTCD = "SYSBP".
60	PO2FIO2	PP ARTERIAL O2/FRACTION INSPIRED O2	Set to LB.LBTEST when LB.LBTEST = "PP Arterial O2/Fraction Inspired O2".
71	NIPPV	NON-INVASIVE POSITIVE PRESSURE VENTILATION	Set to PR.PRTRT when upcase(PR.PRTRT) = "NON-INVASIVE POSITIVE PRESSURE VENTILATION".
74	MCHVENT	MECHANICAL VENTILATION	Set to PR.PRTRT when upcase(PR.PRTRT) = "MECHANICAL VENTILATION".
76	HFOXTHRP	HIGH FLOW OXYGEN	Set to PR.PRTRT when upcase(PR.PRTRT) = "HIGH FLOW OXYGEN THERAPY".

PARAMN	PARAMCD	PARAM	Derivation
80	VSOPRES	VASOPRESSORS AGENTS	Set to CM.CMSCAT when CM.CMCAT = "GENERAL CONCOMITANT MEDICATIONS" and CM.CMSCAT = "VASOPRESSORS AGENTS". Keep only one record per subject per CM.CMSTDTC where CM.CMTRT is not missing.
90	C19NIG	N-BINDING ANTIBODY	Set to IS.ISTEST when IS.ISTESTCD = "C19NIG"
91	HCUICU	SUBJECT IN ICU DUE TO POTENTIAL COVID-19 ILLNESS	Set to "SUBJECT IN ICU DUE TO POTENTIAL COVID-19 ILLNESS" when HOTERM = "ICU" or (SUPPHO.QNAM = "HCUICU" and SUPPHO.QVAL = "Y").
92	HCUHSP	HOSPITALIZED DUE TO COVID-19 ILLNESS?	Set to "HOSPITALIZED DUE TO COVID-19 ILLNESS" when SUPPHO.QNAM = "HCUHSP" and SUPPHO.QVAL = "Y"
95	PRCDTH	PRIMARY CAUSE OF DEATH	Set to "PRIMARY CAUSE OF DEATH" when DD.DDTESTCD = "PRCDTH"
96	SECDTH	SECONDARY CAUSE OF DEATH	Set to DD.DDTEST when DD.DDTESTCD = "SECDTH"
99	DEATH	DEATH	Set to DS.DSDECOD when DS.DSDECOD = "DEATH".

5.2.10 ADC19EF – Covid-19 Efficacy Analysis

The purpose of this dataset is to gather all signs/symptoms/conditions associated with SARS- COV-2 and derive case onset, severe illness onset, and surveillance time for various end point analyses. This dataset contains all derivations to account for surveillance times during blinded placebo-controlled follow-up period, and variables to support the first primary end point and secondary endpoints as defined in the Statistical Analysis Plan. Details around the derivation of surveillance times and the flow charts for identification of first and secondary primary end points are available in [Appendix VI](#) and [Appendix VII](#) respectively. Detailed algorithms for each parameter are included in the define.xml.

Variables used to identify the primary end points as well the other endpoints of special interest are listed in the table below:

PARAMN	PARAMCD	PARAM
40	SARSCOV2	SEVERE ACUTE RESP SYNDROME CORONAVIRUS 2
41	RTCOV2NS	CEPHEID RT-PCR ASSAY OF SARS-COV-2
90	C19NIG	N-BINDING ANTIBODY
91	HCUICU	SUBJECT IN ICU DUE TO POTENTIAL COVID-19 ILLNESS
92	HCUHSP	HOSPITALIZED DUE TO COVID-19 ILLNESS?
95	PRCDTH	PRIMARY CAUSE OF DEATH
96	SECDTH	SECONDARY CAUSE OF DEATH
100	DTHODC19	DEATH OCCURRED DUE TO COVID-19 ILLNESS?
101	PRPDSAD	PRESENCE OF PROTOCOL DEFINED SYMPTOMS AFTER DOSE
102	PRCDCSAD	PRESENCE OF CDC DEFINED SYMPTOMS AFTER DOSE

PARAMN	PARAMCD	PARAM
103	SEVCVS	SEVERE COVID-19 SYMPTOMS - VITAL SIGNS
104	SEVCRF	SEVERE COVID-19 SYMPTOMS - RESPIRATORY FAILURE
105	SEVCVSPR	SEVERE COVID-19 SYMPTOMS - USE OF VASOPRESSORS
106	SEVCRHN	SEVERE COVID-19 SYMPTOMS - SIGNIFICANT ACUTE RENAL, HEPATIC, OR NEUROLOGIC DYSFUNCTION
107	PRSVCSAD	PRESENCE OF PROTOCOL DEFINED SEVERE COVID-19 SYMPTOMS AFTER DOSE
108	PRSCDCAD	PRESENCE OF CDC DEFINED SEVERE COVID-19 SYMPTOMS AFTER DOSE
110	NAATRAD	COVID-19 NAAT RESULT AFTER DOSE
120	C19ONST	PROTOCOL DEFINED COVID-19 ILLNESS ONSET
125	CDCONST	CDC DEFINED COVID-19 ILLNESS ONSET
130	SEVCONST	SEVERE COVID-19 ILLNESS ONSET
135	CDCSONST	CDC DEFINED SEVERE COVID-19 ILLNESS ONSET
141	ST1PD	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 1 FOR PROTOCOL DEFINED SYMPTOMS
142	ST17PD	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 1 FOR PROTOCOL DEFINED COVID19 SYMPTOMS
143	ST2PD	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 2 FOR PROTOCOL DEFINED COVID19 SYMPTOMS
144	ST27PD	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 2 FOR PROTOCOL DEFINED COVID19 SYMPTOMS
145	ST214PD	SUBJECT'S SURVEILLANCE TIME 14 DAYS AFTER DOSE 2 FOR PROTOCOL DEFINED COVID19 SYMPTOMS
151	ST1CD	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 1 FOR CDC DEFINED COVID19 SYMPTOMS
152	ST17CD	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 1 FOR CDC DEFINED COVID19 SYMPTOMS
153	ST2CD	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 2 FOR CDC DEFINED COVID19 SYMPTOMS
154	ST27CD	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 2 FOR CDC DEFINED COVID19 SYMPTOMS
155	ST214CD	SUBJECT'S SURVEILLANCE TIME 14 DAYS AFTER DOSE 2 FOR CDC DEFINED COVID19 SYMPTOMS
161	ST1SE	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 1 FOR PROTOCOL DEFINED SEVERE COVID19 SYMPTOMS
162	ST17SE	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 1 FOR PROTOCOL DEFINED SEVERE COVID19 SYMPTOMS
163	ST2SE	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 2 FOR PROTOCOL DEFINED SEVERE COVID19 SYMPTOMS
164	ST27SE	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 2 FOR PROTOCOL DEFINED SEVERE COVID19 SYMPTOMS
165	ST214SE	SUBJECT'S SURVEILLANCE TIME 14 DAYS AFTER DOSE 2 FOR PROTOCOL DEFINED SEVERE COVID19 SYMPTOMS
171	STC1SE	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 1 FOR CDC DEFINED SEVERE COVID19 SYMPTOMS
172	STC17SE	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 1 FOR CDC DEFINED SEVERE COVID19 SYMPTOMS
173	STC2SE	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 2 FOR CDC DEFINED SEVERE COVID19 SYMPTOMS
174	STC27SE	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 2 FOR CDC DEFINED SEVERE COVID19 SYMPTOMS
175	STC214SE	SUBJECT'S SURVEILLANCE TIME 14 DAYS AFTER DOSE 2 FOR

PARAMN	PARAMCD	PARAM
		CDC DEFINED SEVERE COVID19 SYMPTOMS
201	ST1PDA	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 1 FOR PROTOCOL DEFINED COVID19 SYMPTOMS - ALL AVAILABLE
202	ST17PDA	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 1 FOR PROTOCOL DEFINED COVID19 SYMPTOMS - ALL AVAILABLE
203	ST2PDA	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 2 FOR PROTOCOL DEFINED COVID19 SYMPTOMS - ALL AVAILABLE
204	ST27PDA	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 2 FOR PROTOCOL DEFINED COVID19 SYMPTOMS - ALL AVAILABLE
205	ST214PDA	SUBJECT'S SURVEILLANCE TIME 14 DAYS AFTER DOSE 2 FOR PROTOCOL DEFINED COVID19 SYMPTOMS - ALL AVAILABLE
211	ST1CDA	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 1 FOR CDC DEFINED COVID19 SYMPTOMS - ALL AVAILABLE
212	ST17CDA	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 1 FOR CDC DEFINED COVID19 SYMPTOMS - ALL AVAILABLE
213	ST2CDA	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 2 FOR CDC DEFINED COVID19 SYMPTOMS - ALL AVAILABLE
214	ST27CDA	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 2 FOR CDC DEFINED COVID19 SYMPTOMS - ALL AVAILABLE
215	ST214CDA	SUBJECT'S SURVEILLANCE TIME 14 DAYS AFTER DOSE 2 FOR CDC DEFINED COVID19 SYMPTOMS - ALL AVAILABLE
221	ST1SEA	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 1 FOR PROTOCOL DEFINED SEVERE COVID19 SYMPTOMS - ALL AVAILABLE
222	ST17SEA	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 1 FOR PROTOCOL DEFINED SEVERE COVID19 SYMPTOMS - ALL AVAILABLE
223	ST2SEA	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 2 FOR PROTOCOL DEFINED SEVERE COVID19 SYMPTOMS - ALL AVAILABLE
224	ST27SEA	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 2 FOR PROTOCOL DEFINED SEVERE COVID19 SYMPTOMS - ALL AVAILABLE
225	ST214SEA	SUBJECT'S SURVEILLANCE TIME 14 DAYS AFTER DOSE 2 FOR PROTOCOL DEFINED SEVERE COVID19 SYMPTOMS - ALL AVAILABLE
231	STC1SA	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 1 FOR CDC DEFINED SEVERE COVID19 SYMPTOMS - ALL AVAILABLE
232	STC17SA	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 1 FOR CDC DEFINED SEVERE COVID19 SYMPTOMS - ALL AVAILABLE
233	STC2SA	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 2 FOR CDC DEFINED SEVERE COVID19 SYMPTOMS - ALL AVAILABLE
234	STC27SA	SUBJECT'S SURVEILLANCE TIME 7 DAYS AFTER DOSE 2 FOR CDC DEFINED SEVERE COVID19 SYMPTOMS - ALL AVAILABLE
235	STC214SA	SUBJECT'S SURVEILLANCE TIME 14 DAYS AFTER DOSE 2 FOR CDC DEFINED SEVERE COVID19 SYMPTOMS - ALL AVAILABLE
301	ST1PDX	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 1 FOR PROTOCOL DEFINED COVID19 SYMPTOMS - CROSSOVER
331	STC1SX	SUBJECT'S SURVEILLANCE TIME AFTER DOSE 1 FOR CDC DEFINED SEVERE COVID19 SYMPTOMS - CROSSOVER

5.2.11 ADVA – Immunogenicity Analysis Dataset

This dataset contains immunogenicity assessments for subjects for Phase 1, Phase 2 and pediatric analysis (12-15 years age group and randomly selected subjects from 16-25 years age group). Due to additional follow-up as well as ongoing data cleaning, there may be minor differences due to difference in database snapshots and cutoff dates applied to SDTM and ADaM in this case. Subjects excluded from the evaluable immunogenicity populations were identified

programmatically for samples outside the visit window, not receiving correct vaccination as randomized, no valid assay result; exclusion due to important deviations were provided in SUPPDV dataset.

For Phase 1 for BNT162b2 30 mcg and equivalent Placebo subjects (30 subjects in total), visits ‘V1_DAY1_VAX1_S’, ‘V4_WEEK3_VAX2_S’ and ‘V7_MONTH1_S’ were retested by lab. And for these retested visits (flagged as ‘REPEAT TEST’ in ISTSTDTL), only the retested values were used for analysis.

Assay results collected within a dose-specified sample collection window, either Dose 1 or Dose 2, that were not distinguished by the dose-specified immunogenicity population flags (EVIMMFL for evaluable immunogenicity population, AAIMMFL for all-available immunogenicity population), were excluded from analysis of the corresponding immunogenicity population.

Flags (ABLFL/APSBLFL/ABLPBLFL) used for identifying baseline and post baseline records are also available for each parameter. The ratio from post-baseline to baseline (R2BASE) was calculated as AVAL/BASE for fold rise summaries.

Assay results collected at COVID convalescent visit within 28-42 days after Dose 2, were used for the 1-month post Dose 2 analysis for subjects without a Visit 3 serology assay collected.

Assay results below the corresponding LLOQ were set to 0.5 × LLOQ and missing assay results were not imputed. DTYPE was set to “LLOQIMP” for parameters that needed imputation for LLOQ. All analysis parameters are presented in below table.

Note: When determinate subjects achieved 4-fold rise post baseline, assay results at baseline below the corresponding LLOQ were set to LLOQ.

PARCAT1	PARAMCD	PARAMN	PARAM	ISLLOQ
SEROLOGY	C2NGNT50	1	SARS-CoV-2 serum neutralizing titer 50 (titer) - Virus Neutralization Assay	20
SEROLOGY	C2NGNT90	2	SARS-CoV-2 serum neutralizing titer 90 (titer) - Virus Neutralization Assay	20
SEROLOGY	C19S1IGG	3	COVID-19 S1 IgG (U/mL) - Luminex Immunoassay	1.2665
SEROLOGY	C19RBDIG	4	COVID-19 RBD IgG (U/mL) - Luminex Immunoassay	1.1505
SEROLOGY	C19NIG	5	N-binding antibody - N-binding Antibody Assay	NA
SEROLOGY	NT50_S1	11	SARS-CoV-2 serum neutralizing titer 50 to COVID-19 S1 IgG	NA
SEROLOGY	NT90_S1	12	SARS-CoV-2 serum neutralizing titer 90 to COVID-19 S1 IgG	NA

6. Data Conformance Summary

6.1 Conformance Inputs

Specify the software name and version for the analysis datasets

Pinnacle 21 Enterprise 4.1.4., Validation Engine version 1907.2

Specify the version of the validation rules (i.e. CDISC, FDA) for the analysis datasets

CDISC ADaM-CT 2020-03-27

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

Specify the software name and version for the define.xml

Pinnacle 21 Enterprise 4.1.4.

Specify the version of the validation rules (i.e. CDISC, FDA) for the define.xml

CDISC ADaM CT 2020-03-27

6.2 Issues Summary (Pinnacle 21 Enterprise Validation Report)

Check ID	Diagnostic Message	FDA Severity	Dataset	Count (Issue Rate)	Explanation
AD0018	Variable label mismatch between dataset and ADaM standard	Error	ADVA	3 (4.00%)	On Page 21 of ADaM IG 1.1 descriptive text is allowed at the end of the labels of variables whose names contain indexes "y" or "zz"; Therefore, all labels for variables that contain indexes will throw false positive error messages.
AD0034	PDRMUPFL value is not Y or null	Error	ADC19EF	2089175 (97.22%)	PDRMUPFL is not defined as parameter level flags. It is subject level flags based on series of events therefore having values of Y/N are acceptable.
AD0034	CDRMUPFL value is not Y or null	Error	ADC19EF	2085470 (97.04%)	CDRMUPFL is not defined as parameter level flags. It is subject level flags based on series of events therefore having values of Y/N are acceptable.
AD0099	ASTDY is greater than AENDY	Error	ADC19EF	7579 (0.39%)	ASTDT is greater than AENDT in some cases, as surveillance time could start at various time points for some subjects. For example, a subject's surveillance time could be prior to the start of event due to positive COVID case or other criteria as noted in the define.xml leading to ASTDT > AEDNT and ASTDY > AENDY.
AD0124	Inconsistent value for PARCAT1 within a unique PARAMCD	Error	ADSYMPT	17 (< 0.1%)	Observations for PARAMCD="HCUICU" are included when we have ICU observations from either SDTM HO or from HCUICU observations in SUPPHO. The PARCAT1 differs based on the different categories (HOCAT) picked from the SDTM. Therefore, the different PARCAT1 values for PARAMCD="HCUICU" are acceptable.
AD0253	Record key from SDTM AE is not traceable to ADaM ADAE (not enough ADAE recs)	Error	AE	2192 (5.55%)	AECAT="REACTOGENICITY" records (from diary) was not kept in ADAE (Based on CDISC Vaccine TAUG flat model).

Check ID	Diagnostic Message	FDA Severity	Dataset	Count (Issue Rate)	Explanation
AD0361	Value of ASTDT is greater than value of AENDT	Error	ADC19EF	7579 (0.39%)	ASTDT is greater than AENDT in some cases, as surveillance time could start at various time points for some subjects. For example, a subject's surveillance time could be prior to the start of event due to positive COVID case or other criteria as noted in the define.xml leading to ASTDT > AEDNT and ASTDY > AENDY.
AD1012	Secondary custom variable is present but its primary variable is not present	Warning	ADDS	1 (7.14%)	AD1012 check is limited to "standard" ADaM variables explicitly defined in ADaM IG documents. M1P2EXC is the variable to capture the necessary information. Any new custom variables added to analysis data are out-of-scope for AD1012 check.
AD1012	Secondary custom variable is present but its primary variable is not present	Warning	ADFACEVD	1 (7.14%)	AD1012 check is limited to "standard" ADaM variables explicitly defined in ADaM IG documents. EVENTOCC stands for Occurrences of Event. Any new custom variables added to analysis data are out-of-scope for AD1012 check.
AD1012	Secondary custom variable is present but its primary variable is not present	Warning	ADSL	5 (22.73%)	AD1012 check is limited to "standard" ADaM variables explicitly defined in ADaM IG documents. FUP1CA1N/SCREEN/FUP2CA1N/FPX1CA1N/FUP2CA2N are the variable to capture the necessary information. Any new custom variables added to analysis data are out-of-scope for AD1012 check.
AD1012	Secondary custom variable is present but its primary variable is not present	Warning	ADVA	2 (16.67%)	AD1012 check is limited to "standard" ADaM variables explicitly defined in ADaM IG documents. BSSEROC/BSSERON stands for baseline sero status. Any new custom variables added to analysis data are out-of-scope for AD1012 check.
CT2002	RACE value not found in 'Race' extensible codelist	Warning	ADC19EF	52998 (2.47%)	New terms were added to extensible codelist RACE for the study protocol needs: Multiple
CT2002	RACE value not found in 'Race' extensible codelist	Warning	ADCEVD	6921 (2.55%)	New terms were added to extensible codelist RACE for the study protocol needs: Multiple
CT2002	RACE value not found in 'Race' extensible codelist	Warning	ADCM	230 (1.15%)	New terms were added to extensible codelist RACE for the study protocol needs: Multiple
CT2002	RACE value not found in 'Race' extensible codelist	Warning	ADDS	2915 (2.37%)	New terms were added to extensible codelist RACE for the study protocol needs: Multiple

Study C4591001

Analysis Data Reviewer's Guide

Check ID	Diagnostic Message	FDA Severity	Dataset	Count (Issue Rate)	Explanation
CT2002	RACE value not found in 'Race' extensible codelist	Warning	ADDV	828 (2.23%)	New terms were added to extensible codelist RACE for the study protocol needs: Multiple
CT2002	RACE value not found in 'Race' extensible codelist	Warning	ADFACEVD	58677 (2.60%)	New terms were added to extensible codelist RACE for the study protocol needs: Multiple
CT2002	RACE value not found in 'Race' extensible codelist	Warning	ADMH	2854 (1.45%)	New terms were added to extensible codelist RACE for the study protocol needs: Multiple
CT2002	RACE value not found in 'Race' extensible codelist	Warning	ADSL	1166 (2.42%)	New terms were added to extensible codelist RACE for the study protocol needs: Multiple
CT2002	RACE value not found in 'Race' extensible codelist	Warning	ADSYMPT	9090 (2.77%)	New terms were added to extensible codelist RACE for the study protocol needs: Multiple
CT2002	DTYPE value not found in 'Derivation Type' extensible codelist	Warning	ADVA	12084 (10.57%)	New terms were added to extensible codelist DTYPE for the study protocol needs: LLOQIMP and Derived
CT2002	RACE value not found in 'Race' extensible codelist	Warning	ADVA	2716 (2.37%)	New terms were added to extensible codelist RACE for the study protocol needs: Multiple

7. Submission of Programs

All programs for analysis datasets as well as primary safety and efficacy results are submitted as shown below. All programs were created on a SAS platform using 9.4. ADSL.sas (adsl-sas.txt) must be run first before any other ADaM datasets; all other programs are dependent on ADSL output. ADC19EF program is dependent on ADSYMPPT.

7.1 ADaM Programs

Program Name	Output	Input	Macro Used
adsl-sas.txt	adsl.xpt	dm suppdm ex supplex ds suppds is co lb cm ie dv suppdv vs sv mb suppmb mh pr face ce ho suppho	NA
adds-sas.txt	adds.xpt	ds suppds sv adsl	NA
adae-sas.txt	adae.xpt	ae suppae ex adsl	NA
addv-sas.txt	addv.xpt	dv suppdv adsl	NA
adcm-sas.txt	adcm.xpt	cm suppcm adsl	NA
adcevd-sas.txt	adcevd.xpt	ce face vs ex suppce suppfce suppvvs adsl	NA
adfacevd-sas.txt	adfacevd.xpt	face vs ex suppfce suppvvs adsl	NA
admh-sas.txt	admh.xpt	mh suppmh adsl	NA
adva-sas.txt	adva.xpt	is suppis adsl	NA
adc19ef-sas.txt	adc19ef.xpt	adsympt adsl	NA
adsympt-sas.txt	adsympt.xpt	ce cm dd ds face ho suppho is mb mh lb pr vs adsl	NA

7.2 Analysis Output Programs

Below is the list of outputs for which SAS programs have been provided to replicate the results in the tables. For the more complex outputs, a detailed annotated mock table is also included as a reference (see the link to the individual mocks shown in the table below) to give additional details for each output in [Appendix I](#).

Table	Program Name	Output Name	Title	Input	Population Subset used
1	adsl-s005-demo-ped-saf-sas.txt	adsl_s005_demo_ped_saf.html	Demographic Characteristics – Subjects 12 Through 15 and 16 Through 25 Years of Age – Safety Population	ADSL	ADSL.PHASEN>1 and ADSL.SAFFL eq "Y" and ADSL.MULENRFL ne "Y" and ADSL.AGEGR4N ne .
2	adds-s002-ped-	adds_s002_ped_rand	Disposition of All Randomized Subjects	ADSL ADDS	ADSL.RANDFL eq 'Y' and

Table	Program Name	Output Name	Title	Input	Population Subset used
	rand-sas.txt	.html	Through 1 Month After Dose 2 – Subjects 12 Through 15 and 16 Through 25 Years of Age		ADSL.PHASEN > 1 and ADSL.AGEGR4N ne . and ADSL.MULENRFL ne "Y"
3	adsl-fu-d2-ped-saf-sas.txt	adsl_fu_d2_ped_saf.html	Follow-up Time After Dose 2 – Subjects 12 Through 15 and 16 Through 25 Years of Age – Safety Population	ADSL	ADSL.PHASEN>1 and ADSL.SAFFL eq "Y" and ADSL.MULENRFL ne "Y" and ADSL. AGEGR4N ne .
4	adce-s010-lr-sev-ped-saf-sas.txt	adce_s010_lr_sev_ped_saf.html	Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Subjects 12 Through 15 and 16 Through 25 Years of Age (Reactogenicity Subset) – Safety Population	ADSL ADFACEVD	ADSL.SAFFL eq 'Y' and ADFACEVD.CUTUNBFL ne "Y" and ADSL.PEDREAFL="Y" and ADSL.AGEGR4N ne . and ADSL.HIVFL ne "Y" and ADSL.MULENRFL ne "Y" and ADFACEVD.TR TAN in (8 9) and ADFACEVD.KNOWVFL="Y" and ADFACEVD.FA OBJ in ("PAIN AT INJECTION SITE" "SWELLING" "REDNESS")
5	adce-s020-se-sev-ped-saf-sas.txt	adce_s020_se_sev_ped_saf.html	Systemic Events, by Maximum Severity, Within 7 Days After Each Dose – Subjects 12 Through 15 and 16 Through 25 Years of Age (Reactogenicity Subset) – Safety Population	ADSL ADFACEVD	ADSL.SAFFL eq 'Y' and ADFACEVD.CUTUNBFL ne "Y" and ADSL.PEDREAFL="Y" and ADSL.HIVFL ne "Y" and ADFACEVD.KNOWVFL="Y" and ADFACEVD.TR TAN in (8 9) and ADSL.AGEGR4N ne . and ADSL.MULENRFL ne "Y" and ADFACEVD.FA OBJ not in ("PAIN AT INJECTION SITE" "SWELLING" "REDNESS") and index(uppercase(ADFACEVD.FA OBJ),"HOSPI")=0
6	adae-s091-pd2-ped-saf-sas.txt	adae_s091_pd2_ped_saf.html	Number (%) of Subjects Reporting at Least 1 Adverse Event From Dose 1 Through 1 Month After Dose 2 – Subjects 12 Through	ADSL ADAE	ADSL.SAFFL eq "Y" and ADSL.AGEGR4N ne . and ADSL.MULENRFL ne "Y" and

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

Table	Program Name	Output Name	Title	Input	Population Subset used
			15 and 16 Through 25 Years of Age (Reactogenicity Subset) – Safety Population		ADSL.HIVFL ne 'Y' and ADSL.PEDREAFL eq 'Y'
7	adae-s091-d1-cut-ped-saf-sas.txt	adae_s091_d1_cut_ped_saf.html	Number (%) of Subjects Reporting at Least 1 Adverse Event From Dose 1 Through Cutoff Date (13MAR2021), Subjects 12 Through 15 Years of Age – Safety Population	ADSL ADAE	ADSL.SAFFL eq "Y" and ADSL.MULENRFL ne "Y" and ADSL.AGEGR4N eq 1 and ADSL.HIVFL ne "Y"
8	adva-s001-gmr-ped-ev-eval-sas.txt	adva_s001_gmr_ped_ev_eval.html	Summary of Geometric Mean Ratio – NT50 – Comparison of Subjects 12 Through 15 Years of Age to Subjects 16 Through 25 Years of Age (Immunogenicity Subset) – Subjects Without Evidence of Infection up to 1 Month After Dose 2 – Dose 2 Evaluable Immunogenicity Population	ADSL ADVA	ADVA.EVIMMFL eq 'Y' and ADVA.PARAMN in (1) and 1<ADVA.AVISITN <=6 and ADSL.PEDIMMFL eq "Y" and ADSL.EV1MD2FL eq "Y" and ADVA.ANL01FL eq "Y"
9	adc19ef-ve-cov-7pd2-peds-wo-eval-sas.txt	adc19ef_ve_cov_7pd2_peds_wo_eval.html	Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Subjects 12 Through 15 Years of Age and Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population	ADSL ADC19EF ADSYMPT	ADSL.EVALEFFL='Y' and ADSL.MULENRFL ne "Y" and ADSL.PHASEN ne 1 and ADSL.HIVFL = 'N' and ADC19EF.PDP27FL='Y' and 12 <= ADSL.AGETR01 <= 15
10	adc19ef-ve-cov-7pd2-peds-eval-sas.txt	adc19ef_ve_cov_7pd2_peds_eval.html	Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period – Subjects 12 Through 15 Years of Age and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population	ADSL ADC19EF ADSYMPT	ADSL.EVALEFFL='Y' and ADSL.MULENRFL ne "Y" and ADSL.PHASEN ne 1 and ADSL.HIVFL = 'N' and 12 <= ADSL.AGETR01 <= 15

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

8. Appendix

Appendix I: Annotated Mocks for Key Tables

General note: Each row subsetting is based on N criteria plus additional criteria annotated on the mocks.

Disposition of All Randomized Subjects Through 1 Month After Dose 2 – Subjects 12 Through 15 and 16 Through 25 Years of Age

		Vaccine Group (as Randomized)			
		BNT162b2 (30 µg)		Placebo	
		AGEGR4N		TRT01P	
		12-15 Years	16-25 Years	12-15 Years	16-25 Years
		(N ^a =xx)	(N ^a =xx)	(N ^a =xx)	(N ^a =xx)
		n ^b (%)	n ^b (%)	n ^b (%)	n ^b (%)
Randomized	RANDFL in ('Y')				
Not vaccinated	RANDFL eq 'Y' and (VAX101DT eq . and VAX102DT eq .)				
Vaccinated					
Dose 1	RANDFL eq 'Y' and VAX101DT ne .				
Dose 2	RANDFL eq 'Y' and VAX102DT ne .				
Completed 1-month after Dose 2 visit (vaccination period)	RANDFL eq 'Y' and DSPHASEN=26 and dsdecodn=2	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
Discontinued from vaccination period but continue in the study up to 1-month post-Dose 2 visit					
Discontinued after Dose 1 and before Dose 2	RANDFL eq 'Y' and DSPHASEN=26 and EOTDCDT ne . and (EOSDCDT eq . or EOSDCDT>M1P2CUT>.) and dsdecodn not in (. 2) and (VAX101DT ne . or VAX102DT ne .)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
Discontinued after Dose 2 and before 1-month post-Dose 2 visit	RANDFL eq 'Y' and DSPHASEN=26 and EOTDCDT ne . and (EOSDCDT eq . or EOSDCDT>M1P2CUT>.) and dsdecodn not in (. 2) and vax101dt ne . and vax102dt ne . and (vax102dt <= astdt and (M1PD2DT eq . or astdt<M1PD2DT))	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
Reason for discontinuation from vaccination period					
Adverse event	1. Subset below section with criteria: RANDFL eq 'Y' and DSPHASEN=26 and EOTDCDT ne . and (EOSDCDT eq . or EOSDCDT>M1P2CUT>.) and dsdecodn not in (. 2) and (VAX101DT ne . or VAX102DT ne .)	x	x	x	x
Withdrawal by subject	2. Report by each ADDS. DSDECOD.	x	x	x	x
Physician decision		x	x	x	x
Death		xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)
Study terminated by sponsor					
Pregnancy					
Other					
Withdrawn from the study before 1-month after Dose 2 visit	RANDFL eq 'Y' and DSPHASEN=31 and EOSDCDT ne . and dsdecodn not in (. 2) and (VAX101DT ne . or VAX102DT ne .) and COMPLTDT=. ; where COMPLTDT = ASTDT when DSDECODN=2 and DSPHASEN=26	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)	xx (xxx.x)

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

Withdrawn after Dose 1 and before Dose 2

Withdrawn after Dose 2 and before 1-month post-Dose 2 visit

Reason for withdrawal from the study

Adverse event

Withdrawal by subject

Physician decision

Death

Pregnancy

Other

RANDFL eq 'Y' and DSPHASEN=31 and EOSDCDT ne . and dsdecodn not in (. 2) and vax101dt ne . and (vax102dt eq . or astdt < vax102dt)

RANDFL eq 'Y' and DSPHASEN=31 and EOSDCDT ne . and dsdecodn not in (. 2) and vax101dt ne . and vax102dt ne . and (vax102dt <=astdt and (M1PD2DT eq . or astdt < M1PD2DT))

1. Subset below section with criteria: RANDFL eq 'Y' and DSPHASEN=31 and EOSDCDT ne . and dsdecodn not in (. 2) and (VAX101DT ne . or VAX102DT ne .) and COMPLTDT=.
2. Report by each ADDS. DSDECOD.


Note: Human immunodeficiency virus (HIV)-positive subjects are included in this summary but not included in the analyses of the overall study objectives.
Note: Subjects randomized but did not sign informed consent or had a significant quality event due to lack of PI oversight are not included in any analysis population.
Note: Because of a dosing error, subject[s] C4591001 xxxx xxxxx [and C4591001 xxxx xxxxxx] received an additional dose of BNT162b2 (30 µg) at an unscheduled visit after receiving 1 dose of BNT162b2 (30 µg) and 1 dose of placebo.

- a. N = number of randomized subjects in the specified group. This value is the denominator for the percentage calculations.
- b. n = Number of subjects with the specified characteristic.

PFIZER CONFIDENTIAL SDTM Creation: DDMMMYYYY (HH:MM) Source Data: abcdefgh Table Generation: DDMMMYYYY (HH:MM)

(Cutoff date: ddMmmYYYY, Snapshot Date: ddMmmYYYY) Output File: (CDISC)/C4591001/abcd_XNNN

Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Subjects 12 Through 15 and 16 Through 25 Years of Age (Reactogenicity Subset) – Safety Population



Dose	Local Reaction	12-15 Years			16-25 Years			12-15 Years			16-25 Years		
		N ^a	n ^b (%)	(95% CI) ^c	N ^a	n ^b (%)	(95% CI) ^c	N ^a	n ^b (%)	(95% CI) ^c	N ^a	n ^b (%)	(95% CI) ^c

1	Redness ^d		nn										
	Any	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)
	Mild	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)
	Moderate	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)
	Severe	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)
	Grade 4	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)
	Swelling ^d		nn										
	Any	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)
	Mild	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)
	Moderate	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)
	Severe	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)
	Grade 4	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)	NN	(xx.x)	(xx.x, xx.x)

ADSL.SAFFL eq 'Y' and
ADFACEVD.CUTUNBFL ne "Y" and
ADSL.PEDREAFL="Y" and
ADSL.AGEGR4N ne . and ADSL.HIVFL
ne "Y" and ADSL.MULENRFL ne "Y"
and ADFACEVD.TRTAN in (8 9) and
ADFACEVD.KNOWVFL="Y" and
FAOBJ in ("PAIN AT INJECTION SITE"
"SWELLING" "REDNESS")

ADFACEVD.FATESTCD="MAXSEV"
and ADFACEVD.AVALC ne "" and
ADFACEVD.EVENTFL="Y"

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

Pain at the injection site^e

Study C4591001

Analysis Data Reviewer's Guide

Any	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Mild	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Moderate	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Severe	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Grade 4	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Any local reaction ^f	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)

2 <Repeat for Dose 2>

Any dose <Repeat for any dose>

Note: Reactions were collected in the electronic diary (e-diary) from Day 1 through Day 7 after each dose.

Note: Grade 4 reactions were classified by the investigator or medically qualified person.

- a. N = number of subjects reporting at least 1 yes or no response for the specified reaction after the specified dose.
- b. n = Number of subjects with the specified characteristic.
- c. Exact 2-sided CI based on the Clopper and Pearson method.
- d. Mild: >2.0 to 5.0 cm; moderate: >5.0 to 10.0 cm; severe: >10.0 cm; Grade 4: necrosis (redness and swelling categories) or exfoliative dermatitis (redness category only).
- e. Mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe pain at the injection site.
- f. Any local reaction: any redness >2.0 cm, any swelling >2.0 cm, or any pain at the injection site.

PFIZER CONFIDENTIAL SDTM Creation: DDMMYYYY (HH:MM) Source Data: abcdefgh Table Generation: DDMMYYYY (HH:MM)
 (Cutoff date: ddMmmYYYY, Snapshot Date: ddMmmYYYY) Output File: (CDISC)/C4591001/abcd_XNNN

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

Systemic Events, by Maximum Severity, Within 7 Days After Each Dose – Subjects 12 Through 15 and 16 Through 25 Years of Age (Reactogenicity Subset) – Safety Population

		Vaccine Group (as Administered)											
		BNT162b2 (30 µg)						Placebo					
		12-15 Years			16-25 Years			12-15 Years			16-25 Years		
Dose	Systemic Event	N ^a	n ^b (%)	(95% CI) ^c	N ^a	n ^b (%)	(95% CI) ^c	N ^a	n ^b (%)	(95% CI) ^c	N ^a	n ^b (%)	(95% CI) ^c
1	Fever		nn	(xx.x, xx.x)		nn						nn	
	≥38.0°C		xx.x			xx.x		xx.x		xx.x	NN	xx.x	(xx.x, xx.x)
	≥38.0°C to 38.4°C		xx.x			xx.x		xx.x		xx.x	NN	xx.x	(xx.x, xx.x)
	>38.4°C to 38.9°C		xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)
	>38.9°C to 40.0°C		xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)
	>40.0°C		xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)
	Fatigue ^d		nn			nn						nn	
	Any	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)
	Mild	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)
	Moderate	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)
	Severe	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)
	Grade 4	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)	NN	xx.x	(xx.x, xx.x)

ADSL.SAFFL eq 'Y' and
 ADCE.CUTUNBFL ne 'Y' and
 ADSL.PEDREAFL="Y" and not
 (ADCE.ADT>=ADCE.UNBLNDDT>.) and
 ADSL.HIVFL ne 'Y' and
 ADCE.KNOWVFL="Y" and
 ADCE.TR TAN in (8 9) and
 ADSL.AGEGR4N ne . and
 ADSL.MULENRFL ne 'Y' and FAOBJ
 not in ("PAIN AT INJECTION SITE"
 "SWELLING" "REDNESS") and
 index(uppercase(FAOBJ),"HOSPI")=0

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

Study C4591001

Analysis Data Reviewer's Guide

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

Any	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Mild	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Moderate	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Severe	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Grade 4	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Chills ^d												
Any	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Mild	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Moderate	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Severe	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Grade 4	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Vomiting ^e												
Any	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Mild	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Moderate	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Severe	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Grade 4	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)

Study C4591001

Analysis Data Reviewer's Guide

Diarrhea^f

Any	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Mild	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Moderate	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Severe	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Grade 4	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)

New or worsened muscle pain^d

Any	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Mild	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Moderate	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Severe	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Grade 4	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)

New or worsened joint pain^d

Any	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Mild	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Moderate	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Severe	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Grade 4	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

Any systemic event ^g	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)
Use of antipyretic or pain medication ^h	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)	NN	nn (xx.x)	(xx.x, xx.x)

2 <Repeat for Dose 2>

Any dose <Repeat for any dose>

Note: Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary) from Day 1 through Day 7 after each dose. Grade 4 events were classified by the investigator or medically qualified person.

Note: Subject C4591001 1077 10771278 (13 years of age) experienced systemic events, including a temperature of 40.4°C, on the day of Dose 2. Since these events were recorded as adverse events and not in the e-diary, they do not appear in this table.

- a. N = number of subjects reporting at least 1 yes or no response for the specified event after the specified dose.
- b. n = Number of subjects with the specified characteristic.
- c. Exact 2-sided CI based on the Clopper and Pearson method.
- d. Mild: does not interfere with activity; moderate: some interference with activity; severe: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe fatigue, severe headache, severe muscle pain, or severe joint pain.
- e. Mild: 1 to 2 times in 24 hours; moderate: >2 times in 24 hours; severe: requires intravenous hydration; Grade 4: emergency room visit or hospitalization for severe vomiting.
- f. Mild: 2 to 3 loose stools in 24 hours; moderate: 4 to 5 loose stools in 24 hours; severe: 6 or more loose stools in 24 hours; Grade 4: emergency room visit or hospitalization for severe diarrhea.
- g. Any systemic event: any fever ≥38.0°C, any fatigue, any vomiting, any chills, any diarrhea, any headache, any new or worsened muscle pain, or any new or worsened joint pain.
- h. Severity was not collected for use of antipyretic or pain medication.

PFIZER CONFIDENTIAL SDTM Creation: DDMMYYYY (HH:MM) Source Data: abcdefgh Table Generation: DDMMYYYY (HH:MM)
 (Cutoff date: ddMmmYYYY, Snapshot Date: ddMmmYYYY) Output File: (CDISC)/C4591001/abcd_XNNN

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

ADAЕ.АЕСАТ = 'ADVERSE EVENT' and ADSL.SAFFL="Y" and ADSL.AGEGR4N ne . and ADAЕ.VPHASEN in (1,2) and ADAЕ.V01DT >= ADAЕ.ASTDT and (ADAЕ.UNBLNDDT = . or ADAЕ.UNBLNDDT > ADAЕ.ASTDT) and ADSL.MULENRFL ne "Y" and ADSL.HIVFL ne 'Y' and ADSL.PEDREAFL='Y'

ADSL.SAFFL="Y" and ADSL.AGEGR4N ne . and ADSL.MULENRFL ne "Y" and ADSL.HIVFL ne 'Y' and ADSL.PEDREAFL='Y'

Number (%) of Subjects Reporting at Least 1 Adverse Event From Dose 1 Through 1 Month After Dose 2 – Subjects 12 Through 15 and 16 Through 25 Years of Age (Reactogenicity Subset) – Safety Population

Adverse Event	Vaccine Group			
	BNT162b2 (30 µg)		Placebo	
	12-15 Years (N ^a =xx) n ^b (%)	16-25 Years (N ^a =xx) n ^b (%)	12-15 Years (N ^a =xx) n ^b (%)	16-25 Years (N ^a =xx) n ^b (%)
Any event	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Related ^c	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Severe	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Life-threatening	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Any serious adverse event	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Related ^c	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Severe			xx (xx.x)	xx (xx.x)
Life-threatening			xx (xx.x)	xx (xx.x)
Any adverse event leading to withdrawal			xx (xx.x)	xx (xx.x)
Related ^c	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Severe	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Life-threatening		xx (xx.x)	xx (xx.x)	xx (xx.x)
Death	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)

Note: Adverse events that occurred on the day of or after subjects were unblinded are excluded from this summary.

Note: This table includes all subjects 12 through 15 years of age (all of whom are in the reactogenicity subset) and the subset of subjects 16 through 25 years of age who completed an e-diary.

- a. N = number of subjects in the specified group. This value is the denominator for the percentage calculations.
- b. n = Number of subjects reporting at least 1 occurrence of the specified event category. For “any event,” n = the number of subjects reporting at least 1 occurrence of any event.
- c. Assessed by the investigator as related to investigational product.

PFIZER CONFIDENTIAL SDTM Creation: DDMMYYYY (HH:MM) Source Data: abcdefgh Table Generation: DDMMYYYY (HH:MM)
(Cutoff date: ddMmmYYYY, Snapshot Date: ddMmmYYYY) Output File: (CDISC)/C4591001/abcd_XNNN

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

Summary of Geometric Mean Ratios – NT50 – Comparison of Subjects 12 Through 15 Years of Age to Subjects 16 Through 25 Years of Age (Immunogenicity Subset) – Subjects Without Evidence of Infection up to 1 Month After Dose 2 – Dose 2 Evaluable Immunogenicity Population

Assay	Dose/Sampling Time Point ^a	12-15 Years		16-25 Years		12-15 Years/16-25 Years	
		n ^b	GMT ^c (95% CI ^e)	n ^b	GMT ^c (95% CI ^e)	GMR ^d (95% CI ^d)	Met Noninferiority Objective ^e (Y/N)
SARS-CoV-2 neutralization assay - NT50 (titer)	2/1 Month	xx	xx.x (xx.x, xx.x)	xx	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	Y

Abbreviations: GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NE = not estimable; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Subjects who had no serological or virological evidence of SARS-CoV-2 infection (i.e., SARS-CoV-2 RNA negative [serum swab] at any unscheduled visit up to 1 month after Dose 2 were included in the analysis. Assay results were calculated by exponential distribution). Assay results below the LLOQ were set to 0.5. GMRs and 2-sided 95% CIs were calculated by exponential distribution (based on the Student's t-test). Noninferiority is declared if the lower bound of the 2-sided 95% CI is greater than or equal to 0.67. PFIZER CONFIDENTIAL SDTM Creation: DDMMMYYYY (Cutoff date: ddMmmYYYY, Snapshot Date: ddMmmYYYY)

Number of non-missing ADVA.AVAL

Geometric mean and corresponding 95% CI of ADVA.AVAL

```
Method used:
PROC TTEST DATA=_data12 plots = none;
by _DATASRT
%do _j=1 %to &_maxbyn;
_byvar&_j
%end;
;
class _trt;
VAR log_aval;
RUN;
data ttest;
set stat;
where (ProbF > 0.05 and method = "Pooled") or (ProbF <=0.05 and method = "Satterthwaite");
geomean = exp(mean);
lcl=exp(lowerclmean);
ci = "("||strip(put(exp(lowerclmean),8.2))||", "||strip(put(exp(upperclmean), 8.2))||")";
format geomean 8.2;
keep _datasrt _byvar: geomean lcl ci;
run;
```

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

**Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period
 – Subjects 12 Through 15 Years of Age and Without Evidence of Infection Prior to 7 Days After Dose 2
 – Evaluable Efficacy (7 Days) Population**

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

	Vaccine Group (as Randomized)	Placebo	VE (%)	(95% CI ^e)
	BNT162b2 (30 µg) (N ^a =nn)	(N ^a =nn)		
	Surveillance Time ^c (n2 ^d)	Surveillance Time ^c (n2 ^d)		
	n1 ^b	n1 ^b		
	xxx (nnn)			
Dose 2		x		
≥ 7 days after Dose 2 to < 2 Months after Dose 2	(Sum of ADC19EF.AVAL)/365.25/1000 where ADC19EF.PARAMCD IN ("ST27PD") (For subgroup the surveillance time will be custom and derived at reporting level for each period)	x		
≥ 2 Months after Dose 2 to < 4 Months after Dose 2		x		
	not missing (ADC19EF.VAX102DT) and ADC19EF.VAX102DT + 7 <= ADC19EF.ADT < ADC19EF.VAX102DT + 56	xxx (nnn)	xx.x	(xx.x, xx.x)
≥ 4 Months after Dose 2	not missing (ADC19EF.VAX102DT) and ADC19EF.VAX102DT + 56 <= ADC19EF.ADT < ADC19EF.VAX102DT + 112	xxx (nnn)	xx.x	(xx.x, xx.x)

Abbreviations: N-binding =
SARS-CoV-2 = severe acute
No
bin
swa

ical evidence (prior to 7 days after receipt of the last dose) of past SARS-CoV-2 infection (ie, N-
SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2, and had negative NAAT (nasal
er Dose 2) were included in the analysis.

- a. N = number of subjects in the specified group.
 - b. n1 = Number of subjects meeting the endpoint definition.
 - c. Total surveillance time in 1000 person-years for the given endpoint across all subjects within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period for the overall row and from start to the end of the range stated for each time interval.
 - d. n2 = Number of subjects at risk for the endpoint.
 - e. Confidence interval (CI) for VE is derived based on the Clopper and Pearson method adjusted for surveillance time.
- PFIZER CONFIDENTIAL SDTM Creation: DDMMYYYY (HH:MM) Source Data: abcdefgh Table Generation: DDMMYYYY (HH:MM)
 (Cutoff date: ddMmmYYYY, Snapshot Date: ddMmmYYYY) Output File: (CDISC)/C4591001/abcd_XNNN

Programming note: for this table: remove footnote "Note: Subjects had no serological."

**Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2 – Blinded Placebo-Controlled Follow-up Period
– Subjects 12 Through 15 Years of Age and With or Without Evidence of Infection Prior to 7 Days After Dose 2
– Evaluable Efficacy (7 Days) Population**

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

	Vaccine Group (as Randomized)	Plac			
	BNT162b2 (30 µg) (N ^a =nn)	(N ^a =nn)			
	Surveillance Time ^c (n2 ^d)	n1 ^b	Surveillance Time ^c (n2 ^d)	VE (%)	(95% CI) ^e
	xxx (nnn)		xxx (nnn)	xx.x	(xx.x, xx.x)
≥7 days after Dose 2 to <2 Months after Dose 2	(Sum of ADC19EF.AVAL)/365.25/1000 where ADC19EF.PARAMCD IN ("ST27PD") (For subgroup the surveillance time will be custom and derived at reporting level for each period)		xxx (nnn)	xx.x	(xx.x, xx.x)
≥2 Months after Dose 2 to <4 Months after Dose 2	not missing (ADC19EF.VAX102DT) and ADC19EF.VAX102DT + 7 <= ADC19EF.ADT < ADC19EF.VAX102DT + 56		xxx (nnn)	xx.x	(xx.x, xx.x)
≥4 Months after Dose 2	not missing (ADC19EF.VAX102DT) and ADC19EF.VAX102DT + 56 <= ADC19EF.ADT < ADC19EF.VAX102DT + 112		xxx (nnn)	xx.x	(xx.x, xx.x)

ADSL.EVALEFFL="Y" and ADC19EF.PARAMCD="C19ONST" and index(uppercase(ADC19EF.AVALC), "POS")>0 and ADC19EF.PDRMUPFL="N" and ADC19EF.ILD27FL="Y" and ADC19EF.FILOCRFL="Y" and ((not missing (DVSTDT) and adt <= DVSTDT) or missing(DVSTDT))

ADSL.TRT01P

ADSL.EVALEFFL="Y" and ADC19EF.PDP27FL="Y" and ADSL.AGEGR4N=1

(Sum of ADC19EF.AVAL)/365.25/1000 where ADC19EF.PARAMCD IN ("ST27PD")
(For subgroup the surveillance time will be custom and derived at reporting level for each period)

ADC19EF.PDRMUPFL = "N" AND ADC19EF.PDP27FL = "Y" AND ADC19EF.PARAMCD IN ("ST27PD") AND ADC19EF.AVAL > 0

not missing (ADC19EF.VAX102DT) and ADC19EF.VAX102DT + 7 <= ADC19EF.ADT < ADC19EF.VAX102DT + 56

not missing (ADC19EF.VAX102DT) and ADC19EF.VAX102DT + 112 <= ADC19EF.ADT

Abbreviations: N-binding = SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; N-binding swab = nasal swab; NAAT = nucleic acid amplification test; N = number of subjects in the specified group; n1 = Number of subjects meeting the endpoint definition; Total surveillance time in 1000 person-years for the given endpoint across all subjects within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period for the overall row and from start to the end of the range stated for each time interval. n2 = Number of subjects at risk for the endpoint. Confidence interval (CI) for VE is derived based on the Clopper and Pearson method adjusted for surveillance time.

Appendix II: Analysis plan AE windowing logic

AEs that occurred on the same day of a dose and without detailed AE start time are considered as occurring after dose but not considered as immediate AEs. An immediate AE is defined as an AE that occurred within 30 minutes (including 30 minutes) after dose.

AEs without start time and started on the same day of Dose x or AEs (with start time) started on or after the timepoint of dose x are included in 'AE's from dose x to 7 days after dose x', 'AE's from dose x to 1 months after dose x' and 'AE's from dose x to 6 months after dose x' window. Dose x could be Dose 1, Dose 2, Dose 3 or Dose 4.

ADAE.VPHASE is derived based on AE window per the table below:

VPHASE		Comments
Pre-Vaccination	Event start before Dose 1	Blinded placebo-controlled period
Vaccination 1	Event start on or after Dose 1 and before Dose 2	Blinded placebo-controlled period
Vaccination 2	Event started on or after Dose 2 and before or on the day of 1 month follow up visit after Dose 2 (ADSL.V01DT) See details in below section for ADSL.V01DT	Blinded placebo-controlled period
Follow Up 1	Event start after the day of 1 month follow up visit after Dose 2 (ADSL.V01DT) and before or on the day of 6 months follow up visit after Dose 2 (ADSL.V02DT) See details in below section for ADSL.V02DT	Blinded placebo-controlled period
Follow Up 2	Event start after the day of 6 months follow up visit after Dose 2 (ADSL.V02DT) and before unblinding	Blinded placebo-controlled period
After unblinding and before Vaccination 3	Event start on or after unblinding and Dose 3 is missing	Open label follow-up period
	Event start on or after unblinding and before Dose 3	Open label follow-up period
Vaccination 3	Event start on or after Dose 3 and before Dose 4	Open label follow-up period
Vaccination 4	Event start on or after Dose 4 and before or on 1 month follow up visit after Dose 4 (ADSL.V03DT) See details in below section for ADSL.V03DT	Open label follow-up period
Follow Up 3	Event start after 1 month follow up visit after Dose 4 and before or on the day of 6 months	Open label follow-up

VPHASE		Comments
	follow up visit after Dose 4 (ADSL.V04DT) See details in below section for ADSL.V04DT	period
Follow Up 4	Event start after the day of 6 months follow up visit after Dose 4 (ADSL.V04DT)	Open label follow-up period

For Phase 1 for BNT162b2 30 mcg and Equivalent Placebo Subjects:

For AE's from Dose 1 to 1 month after Dose 2 (Blinded placebo-controlled period):

- Dose 1 start date \leq ae start date \leq 1 month follow up date or the day before unblinding which one is earlier (ADSL.V01DT)
V01DT is the blood sample collected date from visit 7.

If visit 7 blood sample collection date is not available from CO dataset, then use the date of visit 7 from SV dataset.

Else if date of visit 7 is not available, then use date of Dose 2 + 35 days

Else if date of Dose 2 is not available, then use date of Dose 1 + 35 + 23 days

Note: if a subject was unblinded before visit 7 (V01DT), then ADSL.V01DT was reset to the day before unblinding. ADSL.V01DT=min (V01DT, ADSL.UNBLNDDT-1).

For AE's from Dose 1 to 6 months after Dose 2 (Blinded placebo-controlled period):

- Dose 1 start date \leq ae start date \leq 6 months follow up date or the day before unblinding which one is earlier (ADSL.V02DT)
V02DT is the blood sample collected date from visit 8.

If visit 8 blood sample collection date is not available from CO dataset, then use the date of visit 8 from SV dataset.

Else if date of visit 8 from SV dataset is not available, then use date of Dose 2 + 189 days

Else if date of Dose 2 is not available, then use date of Dose 1 + 189 + 23 days

Note: if a subject was unblinded before visit 8 (V02DT), then ADSL.V02DT was reset to the day before unblinding. ADSL.V02DT=min (V02DT, ADSL.UNBLNDDT-1).

For AE's from Dose 1 to 6 months after Dose 2 (Whole study period without considering unblinding):

- Dose 1 start date \leq ae start date \leq 6 months follow up date (ADSL.V02OBDT)
V02OBDT is the blood sample collected date from visit 8.

If visit 8 blood sample collection date is not available from CO dataset, then use the date of visit 8 from SV dataset.

Else if date of visit 8 from SV dataset is not available, then use date of Dose 2 + 189 days

Else if date of Dose 2 is not available, then use date of Dose 1 + 189 + 23 days

ADSL.V03DT is the date of visit 103 (1-month post dose 4 for follow up vaccination period) from SV after unblinding.

If date of visit 103 from SV dataset is not available, then use date of Dose 4 + 35 days

Else if date of Dose 4 is not available, then use date of Dose 3 + 35 + 23 days

ADSL.V04DT is the date of visit 104 (6-months post dose 4 for follow up period) from SV after unblinding.

If date of visit 104 from SV dataset is not available, then use date of Dose 4 + 189 days

Else if date of Dose 4 is not available, then use date of Dose 3 + 189 + 23 days

For Phase 2/3:

For AE's from Dose 1 to 1 month after Dose 2 (Blinded placebo-controlled period):

- Dose 1 start date \leq ae start date \leq 1 month follow up date or the day before unblinding which one is earlier (ADSL.V01DT)
V01DT is the blood sample collected date from visit 3.

If visit 3 blood sample collection date is not available from CO dataset, then use the date of visit 3 from SV dataset.

Else if date of visit 3 is not available, then use date of Dose 2 + 35 days

Else if date of Dose 2 is not available, then use date of Dose 1 + 35 + 23 days

Note: if a subject was unblinded before visit 3 (V01DT), then ADSL.V01DT was reset to the day before unblinding. $ADSL.V01DT = \min(V01DT, ADSL.UNBLNDDT-1)$.

For AE's from Dose 1 to 6 months after Dose 2 (Blinded placebo-controlled period):

- Dose 1 start date \leq ae start date \leq 6 months follow up date or the day before unblinding which one is earlier (ADSL.V02DT)
V02DT is the blood sample collected date from visit 4.

If visit 4 blood sample collection date is not available from CO dataset, then use the date of visit 4 from SV dataset.

Else if date of visit 4 from SV dataset is not available, then use date of Dose 2 + 189 days

Else if date of Dose 2 is not available, then use date of Dose 1 + 189 + 23 days

Note: if a subject was unblinded before visit 4 (V02DT), then ADSL.V02DT was reset to the day before unblinding. $ADSL.V02DT = \min(V02DT, ADSL.UNBLNDDT-1)$.

For AE's from Dose 1 to 6 months after Dose 2 (Whole study period without considering unblinding):

- Dose 1 start date \leq ae start date \leq 6 months follow up date (ADSL.V02OBDT)
V02OBDT is the blood sample collected date from visit 4.

If visit 4 blood sample collection date is not available from CO dataset, then use the date of visit 4 from SV dataset.

Else if date of visit 4 from SV dataset is not available, then use date of Dose 2 + 189 days

Else if date of Dose 2 is not available, then use date of Dose 1 + 189 + 23 days

Note: if a subject took Dose 3 in open label vaccination period before V02OBDT, then ADSL.V02OBDT was reset to the day before Dose 3. $ADSL.V02OBDT = \min(V02OBDT, ADSL.VAX201DT-1)$.

ADSL.V03DT is the date of visit 103 (1-month post dose 4 for follow up vaccination period) from SV after unblinding.
 If date of visit 103 from SV dataset is not available, then use date of Dose 4 + 35 days
 Else if date of Dose 4 is not available, then use date of Dose 3 + 35 + 23 days

ADSL.V04DT is the date of visit 104 (6-months post dose 4 for follow up period) from SV after unblinding.
 If date of visit 104 from SV dataset is not available, then use date of Dose 4 + 189 days
 Else if date of Dose 4 is not available, then use date of Dose 3 + 189 + 23 days

Appendix III: Handling of Incomplete Dates

Adverse events

Incomplete AE start and stop dates were imputed as follows:

Imputation only applied to partial AE start dates (missing day, missing both month and day). The purpose of imputation was only for allocating analysis interval on AE summary, the original partial date format was recorded or kept in the data and listings. No imputation on Diary data from subjects or symptom resolved date from Investigator collected as partial date. No imputation is carried out for completely missing AE start dates. No imputation is carried out for partial or completely missing AE stop dates. All information on AE stop date was used for imputation logic check as part of the imputation rules for partial AE start date.

Pfizer imputation rule applied:

Rules	Programming Logic
General rules	Imputation only applies to partial AE start dates (missing day, missing both month and day). The purpose of imputation is only for allocating analysis interval on AE summary, the original partial date format should be recorded or kept in the data and listings. No imputation on Diary data from subjects or symptom resolved date from Investigator collected as partial date. General Pfizer imputation rule applied: For Start date: <ul style="list-style-type: none"> - For missing Day: impute Day = first day of the month (01), e.g. November 1990 is treated as 01NOV1990 - For missing Month and Day: impute Month = first month of the year (JAN), impute Day = first day of the month (01), e.g. 1990 is treated as 01JAN1990

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

Rules	Programming Logic
	For Stop date: <ul style="list-style-type: none"> - For missing Day: impute Day = last day of the month (30 or 31), e.g. November 1990 is treated as 30NOV1990 - For missing Month and Day: impute Month = first month of the year (DEC), impute Day = last day of the month (31), e.g. 1990 is treated as 31DEC1990
completely missing start dates	No imputation
completely missing stop dates	No imputation
partial stop dates	No imputation
the day portion of ASTDTM was initially missing	<ul style="list-style-type: none"> • Apply general imputation first, after general Pfizer imputation rule is applied, compare the month of the AE start date (ASTDTM) with the month of subsequent doses/vaccinations (EXSTDTC) • If the start date MONTH and YEAR of (ASTDTM) and any of the subsequent dose dates MONTH and YEAR of (EXSTDTC) are equal, and the stop date (AENDTM) is later than the dose date (EXSTDTC), whether the stop date (AENDTM) comes from partial or complete dates, or AE stop date is missing then reset ASTDTM to numeric value of first EXSTDTC of that month. • Otherwise if the AE start date MONTH and YEAR of (ASTDTM) do not match any month of subsequent doses/vaccination (EXSTDTC) MONTH and YEAR, or the stop date (AENDTM) comes from partial or complete dates is earlier than corresponding EXSTDTC, don’t do the second imputation and retain the first imputation
day and month portion of ASTDTM were initially missing	<ul style="list-style-type: none"> • Apply general imputation first, compare the imputed AE start date (ASTDTM) with the dosing dates (EXSTDTC) in the same calendar year and the AE stop date (AENDTM). If the stop date is earlier than the earliest dosing date in the same calendar year, the AE start date will remain the first day of the calendar year. Otherwise, the AE start date (ASTDTM) will be imputed to the earliest dosing date (EXSTDTC) in that calendar year that is less than the AE stop date (AENDTM).

Concomitant medications/medical histories

Incomplete CM/MH start and stop dates were imputed as follows:

Imputation applied to partial CM/MH start dates and stop dates (missing day, missing both month and day). For partial start dates, if missing start day, the first day of the month was used; if missing start month and day, the first month of the year was used. For partial stop dates, if missing stop day, the last day of the month was used; if missing stop month and day, the last month of the year was used.

Appendix IV: ADFACEVD Analysis Parameters

PARCAT1	PARCAT2	PARAM	PARAMCD
REACTOGENICITY	ADMINISTRATION SITE	Hospitalized for injection site pain occurrence indicator	OCHIS
REACTOGENICITY	ADMINISTRATION SITE	Pain at injection site maximum severity	MSPIS
REACTOGENICITY	ADMINISTRATION SITE	Pain at injection site occurrence indicator	OCPIS
REACTOGENICITY	ADMINISTRATION SITE	Pain at injection site severity/intensity	SEVPIS
REACTOGENICITY	ADMINISTRATION SITE	Redness diameter cm	DIARE
REACTOGENICITY	ADMINISTRATION SITE	Redness grade 4 criteria met	G4CRR
REACTOGENICITY	ADMINISTRATION SITE	Redness maximum diameter	MDIRE
REACTOGENICITY	ADMINISTRATION SITE	Redness maximum diameter cm	MADRE
REACTOGENICITY	ADMINISTRATION SITE	Redness maximum severity	MSERE
REACTOGENICITY	ADMINISTRATION SITE	Redness minimum diameter cm	MIDRE
REACTOGENICITY	ADMINISTRATION SITE	Redness occurrence indicator	OCISR
REACTOGENICITY	ADMINISTRATION SITE	Redness severity/intensity	SEVREDN
REACTOGENICITY	ADMINISTRATION SITE	Swelling diameter cm	DIASW
REACTOGENICITY	ADMINISTRATION SITE	Swelling grade 4 criteria met	G4CRS
REACTOGENICITY	ADMINISTRATION SITE	Swelling maximum diameter	MDISW
REACTOGENICITY	ADMINISTRATION SITE	Swelling maximum diameter cm	MADSW
REACTOGENICITY	ADMINISTRATION SITE	Swelling maximum severity	MSESW
REACTOGENICITY	ADMINISTRATION SITE	Swelling minimum diameter cm	MIDSW
REACTOGENICITY	ADMINISTRATION SITE	Swelling occurrence indicator	OCINS
REACTOGENICITY	ADMINISTRATION SITE	Swelling severity/intensity	SEVSWEL
REACTOGENICITY	MEDICATIONS GIVEN	Medications duration	MEDDUR
REACTOGENICITY	MEDICATIONS GIVEN	Medications medication to treat fever or pain	MEDTFVPN
REACTOGENICITY	MEDICATIONS GIVEN	Medications stop date meds given to trt/pnt symptoms	STPDMEDP
REACTOGENICITY	SYSTEMIC	Chills maximum severity	MAXCHIL
REACTOGENICITY	SYSTEMIC	Chills occurrence indicator	OCCHILLS
REACTOGENICITY	SYSTEMIC	Chills severity/intensity	SEVCHIL
REACTOGENICITY	SYSTEMIC	Diarrhea maximum severity	MAXDIAR

PARCAT1	PARCAT2	PARAM	PARAMCD
REACTOGENICITY	SYSTEMIC	Diarrhea occurrence indicator	OCDIAR
REACTOGENICITY	SYSTEMIC	Diarrhea severity/intensity	SEVDIAR
REACTOGENICITY	SYSTEMIC	Fatigue maximum severity	MAXSFAT
REACTOGENICITY	SYSTEMIC	Fatigue occurrence indicator	OCFATIG
REACTOGENICITY	SYSTEMIC	Fatigue severity/intensity	SEVFATI
REACTOGENICITY	SYSTEMIC	Fever maximum temperature	MAXTEMP
REACTOGENICITY	SYSTEMIC	Fever occurrence indicator	OCFEVER
REACTOGENICITY	SYSTEMIC	Headache maximum severity	MAXSHEA
REACTOGENICITY	SYSTEMIC	Headache occurrence indicator	OCHEAD
REACTOGENICITY	SYSTEMIC	Headache severity/intensity	SEVHEAD
REACTOGENICITY	SYSTEMIC	Hospitalized for chills occurrence indicator	OCHOCIL
REACTOGENICITY	SYSTEMIC	Hospitalized for diarrhea occurrence indicator	OCHODI
REACTOGENICITY	SYSTEMIC	Hospitalized for headache occurrence indicator	OCHOHE
REACTOGENICITY	SYSTEMIC	Hospitalized for joint pain occurrence indicator	OCHOJP
REACTOGENICITY	SYSTEMIC	Hospitalized for muscle pain occurrence indicator	OCHOMP
REACTOGENICITY	SYSTEMIC	Hospitalized for tiredness (fatigue) occurrence indicator	OCHOFA
REACTOGENICITY	SYSTEMIC	Hospitalized for vomiting occurrence indicator	OCHOVO
REACTOGENICITY	SYSTEMIC	Joint pain maximum severity	MAXSJP
REACTOGENICITY	SYSTEMIC	Joint pain occurrence indicator	OCJOPAIN
REACTOGENICITY	SYSTEMIC	Joint pain severity/intensity	SEVJOIN
REACTOGENICITY	SYSTEMIC	Muscle pain maximum severity	MAXSMP
REACTOGENICITY	SYSTEMIC	Muscle pain occurrence indicator	OCMPNIS
REACTOGENICITY	SYSTEMIC	Muscle pain severity/intensity	SEVMUSP
REACTOGENICITY	SYSTEMIC	Vomiting maximum severity	MAXSVOM
REACTOGENICITY	SYSTEMIC	Vomiting occurrence indicator	OCVOMI
REACTOGENICITY	SYSTEMIC	Vomiting severity/intensity	SEVVOMI

Appendix V: External files used during ADaM dataset creation

The following files were used in the creation of specific ADaM datasets to identify specific subsets of subjects (e.g., Phase 1, Phase 2, Phase 3) as well as categories of medical history data used as comorbidities. A copy of the data included in these files was combined into a supplementaldatadefinitions.pdf file and is linked to the define.xml package for reference.

ID	File Name	Comments
Rheumatic	Report-CCI-Rheumatic.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Renal	Report-CCI-Renal.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Pulmonary	Report-CCI-Pulmonary.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Periph vasc	Report-CCI-Periph vasc.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Peptic ulcer	Report-CCI-Peptic ulcer.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Mod sev liver	Report-CCI-Mod sev liver.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Mild liver	Report-CCI-Mild liver.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
MI	Report-CCI-Mi.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

ID	File Name	Comments
Metastatic tumour	Report-CCI-Metastatic tumour.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Lymphoma	Report-CCI-Lymphoma.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Leukemia	Report-CCI-Leukemia.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Hemiplegia	Report-CCI-Hemiplegia.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Diabetes without comp	Report-CCI-Diabetes without comp.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Diabetes with comp	Report-CCI-Diabetes with comp.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Dementia	Report-CCI-Dementia.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
CHF	Report-CCI-CHF.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Cerebrovascular	Report-CCI-Cerebrovascular.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)

ID	File Name	Comments
Any malignancy	Report-CCI-Any malignancy.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
AIDS HIV	Report-CCI-AIDS HIV.xlsx	Used for ADMH creation to flag the medical history terms with comorbidities (record level) Used for ADSL creation to flag the subject with comorbidities (subject level)
Comorbidity Categories	Comorbidity-Categories.xlsx	Used for ADMH creation to derive the Charlson Comorbidity Index categories by record level. One MH term may meet multiple Charlson Comorbidity Index categories.
Phase1	C4591001-Phase 1 subjects from DMW.xlsx	Used for ADSL creation to flag the subjects from Phase 1
Phase2	first-C4591001-360-participants-enrolled-V1.0-13Aug2020-update.xlsx	Used for ADSL creation to flag the subjects from Phase 2 DS360 subset
Phase3 DS6000	newlist-C4591001-6k-participants-enrolled-V3.0-17sep2020.csv	Used for ADSL creation to flag the subjects from Phase 3 DS6000 subset
HIV PT	201114 HIV preferred terms.xlsx	Used for ADSL creation to flag the HIV Positive
EUA 12-25 Age group	C4591001-subject-list-for-12-25-immuno-analysis-27Jan2021.xlsx	Used for ADSL creation to flag the subjects from EUA 12-25 subset
BMI scale	BMI-12-15-Scale.xlsx	Used for ADSL creation to flag the obese subjects for 12-15 years age group

Appendix VI: Surveillance Times

Start-of-surveillance time:

For all VE-related endpoints in this study, the start-of-surveillance times are summarized as follows:

Endpoint's Associated Participant-Level Population	Start-of-Surveillance Time
Evaluable Efficacy (7 days)	Dose 2 + 7 days (Day 8 relative to Dose 2)
Dose 2 All-available Efficacy	Dose 2 + 7 days (Day 8 relative to Dose 2)
Dose 1 All-available Efficacy	Dose 1 (Day 1 relative to Dose 1)

End-of-surveillance time:

The end of surveillance time is then determined considering the following events:

1. When the first COVID-19 case occurs.
2. When the participant’s end of the study occurs due to, e.g. withdrawal or death or trial completion etc.
3. When the participant has first important protocol violation.
4. When the participant is unblinded at the time of being eligible for receipt of BNT162b2 or other reasons.

For all VE-related endpoints in this study, the end of a surveillance period for each participant is summarized below:


Endpoint's Associated Participant-Level Population	End-of-Surveillance Time
Evaluable Efficacy	Earliest of event (1), (2), (3) and (4)
Dose 2 All-available Efficacy	Earliest of event (1) and (2) and (4)
Dose 1 All-available Efficacy	Earliest of event (1) and (2) and (4)

Using the above start and stop times for surveillance time, the overall surveillance time is derived as: End-of-surveillance time – Start-of-surveillance time + 1

Appendix VII: Efficacy Flow Charts

1. The flowchart for deriving the COVID-19 cases included below for the first primary endpoints in evaluable efficacy participants with no serological or virological evidence of past SARS-CoV-2 infection:

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)




The central laboratory NAAT result will be used for the case definition, unless no result is available from the central laboratory, in which case a local NAAT result may be used if it was obtained using 1 of the following assays:

- a. Cepheid Xpert Xpress SARS-CoV-2

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

- b. Roche cobas SARS-CoV-2 real-time RT-PCR test (EUA200009/A001)
 - c. Abbott Molecular/RealTime SARS-CoV-2 assay (EUA200023/A001)
2. The flowchart for deriving the COVID-19 cases included below for the second primary endpoints in evaluable efficacy participants:

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)



Appendix VIII: Detailed subsetting for Analysis:

1. Key Analysis Population Subsetting:

Safety and Immunogenicity Analysis

Table Category	Analysis Population		Total Number of Subjects (N)			Subset Condition for Total N
			12-15 Years	16-25 Years	Total	
Conduct of Study	Randomized		1120	12489	8646	ADSL.PHASEN>1 and ADSL.RANDFL="Y" and ADSL.MULENRFL^="Y" and ADSL.AGEGR4N ^=.
	Safety		2260	3770	6030	ADSL.PHASEN>1 and ADSL.SAFFL="Y" and ADSL.MULENRFL^="Y" and ADSL.AGEGR4N ^=.
Adverse Events (Reactogenicity Subset)	Safety population for AEs reporting from Dose 1		2260	1097	3357	ADSL.SAFFL="Y" and ADSL.MULENRFL^="Y" and ADSL.HIVFL^="Y" and PEDREAFL="Y"
	Safety population for AEs reporting from Dose 2		2241	1058	3299	ADSL.SAFFL="Y" and ADSL.MULENRFL^="Y" and ADSL.HIVFL^="Y" and PEDREAFL="Y" and ADSL.VAX102DT>. and ADSL.VAX101=ADSL.VAX102 and (ADSL.VAX102DT<ADSL.UNBLNDDT or ADSL.UNBLNDDT=.)
Reactogenicity ^a	Safety (Reactogenicity subset)	Dose 1	2260	1098	3358	ADSL.SAFFL="Y" and ADSL.MULENRFL^="Y" and ADSL.VAX101 ne "" and PEDREAFL="Y"
		Dose 2	2241	1060	3301	ADSL.SAFFL="Y" and ADSL.MULENRFL^="Y" and ADSL.VAX102 ^="" and PEDREAFL="Y"
Immunogenicity	Dose 2 All-Available		246	225	471	ADSL.PEDIMMFL="Y" and ADSL.AAI02FL="Y"
	Dose 2 Evaluable		245	218	463	ADSL.PEDIMMFL="Y" and ADSL.EVAL02FL="Y"

a. For reactogenicity, the N listed here is the number of subjects in reactogenicity subset relative for the specified dose (Including HIV positive and not transmitted e-diary subjects). And the numbers match with the number of subjects in e-diary transmission table (number of subjects vaccinated at Dose 1/Dose2). The N in the maximum severity tables are the number of HIV negative subjects reporting at least 1 yes or no

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

response before unblinding for the specified reaction/events after the specified dose which is less than the N in this table. For the detailed algorithm, please refer to [Appendix I](#).

2. Adverse Event Analysis Reporting Period Subsetting:

Reporting Period		Subset condition to determine the AEs within corresponding reporting period. (Note: Additional subset for analysis population is needed)
Blinded Placebo-Controlled Follow-up Period	Immediate adverse event after Dose 1	ADAE.AECAT='ADVERSE EVENT' and ADAE.AEIMMFL='Y' and ADAE.VPHASEN=1
	Immediate adverse event after Dose 2	ADAE.AECAT='ADVERSE EVENT' and ADAE.AEIMMFL='Y' and ADAE.VPHASEN=2
	From Dose 1 to 7 days after Dose 1	ADAE.AECAT='ADVERSE EVENT' and ADAE.VPHASEN=1 and ADSL.VAX101DT<=ADAE.ASTDT <=ADSL.VAX101DT+7
	From Dose 2 to 7 days after Dose 2	ADAE.AECAT='ADVERSE EVENT' and ADAE.VPHASEN=2 and ADSL.VAX102DT<=ADAE.ASTDT <=ADSL.VAX102DT+7
	From Dose 1 to 1 month after Dose 2	ADAE.AECAT='ADVERSE EVENT' and ADAE.VPHASEN in (1,2)
	From Dose 1 to unblinding (the day before unblinding)	ADAE.AECAT='ADVERSE EVENT' and ADAE.VPHASEN in (1,2,3,99)
Blinded Placebo-Controlled Follow-up Period + Open-label follow up period for subjects who originally received BNT162b2	From Dose 1 to 6 Month after Dose 2 Note: This is for subjects originally received BNT162b2 and with at least 6 months of follow up time after Dose 2 (28*6 days after Dose 2), Including all of the AEs within 6-month after Dose 2 regardless of unblinding or not	ADAE.AECAT='ADVERSE EVENT' and ADAE.VPHASEN>=1 and . <ADAE.ASTDT<=ADSL.V02OBDT
Open label follow-up period for subjects who received placebo and then received BNT162b2 After unblinding	Immediate adverse event after Dose 3 (1st dose of BNT162b2 after unblinding)/Dose 4 (2nd dose of BNT162b2 after unblinding)	ADAE.AECAT='ADVERSE EVENT' and ADAE.AEIMMFL='Y' and ADAE.VPHASEN in (5, 6)
	From Dose 3 (1 st dose of BNT162b2 after unblinding) to 7 days after Dose 3	ADAE.AECAT='ADVERSE EVENT' and ADAE.VPHASEN=5 and ADSL.VAX201DT<=ADAE.ASTDT <=ADSL.VAX201DT+7
	From Dose 4 (2 nd dose of BNT162b2 after unblinding) to 7 days after Dose 4	ADAE.AECAT='ADVERSE EVENT' and ADAE.VPHASEN=6 and ADSL.VAX202DT<=ADAE.ASTDT <=ADSL.VAX202DT+7
	From Dose 3 (1 st dose of BNT162b2 after unblinding) to the date of cutoff	ADAE.AECAT='ADVERSE EVENT' and ADAE.VPHASEN>=5 and ADAE.VPHASEN ne 99 and .<ADAE.ASTDT<=ADSL.X1CSRDT

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)

Reporting Period		Subset condition to determine the AEs within corresponding reporting period. (Note: Additional subset for analysis population is needed)
Open label follow-up period for subjects who originally received BNT162b2	From unblinding date to the date of cutoff	ADAE.AECAT='ADVERSE EVENT' and ADAE.VPHASEN>=4 and ADAE.VPHASEN ne 99 and .<ADAE.ASTDT<=ADSL.X1CSRDT

Immediate AEs were those events occurring within the first 30 minutes after each dose, which were flagged as “Y” in ADAE.AEIMMFL.

090177e198e31cd5\Final\Final On: 15-Dec-2021 18:40 (GMT)